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ABSTRACT 
The body‘s remarkable ability to repair itself from damage is both very useful and 
extremely complex. The wound healing system is characterised by four 
overlapping phases: hemostasis, inflammation, proliferation, and remodelling. It is 
designed to heal rapidly and efficiently any breach in the protective barrier we call 
skin, in order to restore normal body function in the quickest possible time. 
However, pathological conditions such as keloids or hypertrophic scar may arise 
if events in the wound healing cascade are not coordinated properly, which can 
lead to loss of skin function and disfigurement. The purpose of this study was to 
determine whether myostatin plays a role in the healing of burn wounds in skin. 
Myostatin is best known for its powerful negative regulation of muscle 
development. Absence of myostatin results in a heavy muscling phenotype, 
whereas over-expression is associated with muscle wasting conditions. Recently, 
myostatin has been shown to be involved in muscle wound healing, where 
knockout of the myostatin gene resulted in improved healing, with decreased 
fibrotic scar tissue formation. It is noteworthy that the cell surface receptor to 
which myostatin binds is also present in skin. In consideration of this information 
the prospect of myostatin involvement in skin biology represents a gap in 
scientific knowledge. Therefore, the present investigation was designed to 
ascertain whether the effects of myostatin in muscle regeneration can also be 
seen in skin wound healing. To this end, a mouse burn wound model was 
designed to determine the efficacy of antagonising myostatin to bring about 
improved healing and decreased fibrosis of skin burns. Wounds of mice treated 
with the myostatin antagonist showed no significant difference compared to 
saline-treated controls in collagen content at any time point. Gene expression 
studies on TGF-β1, TGF-β3, decorin and fibromodulin revealed that differences 
between antagonist-treated and saline-treated groups were possibly masked by 
the effect of the burn injury but were present in uninjured skin. Similarly, uninjured 
skin of antagonist-treated animals exhibited a significantly higher fluid content 
than uninjured skin of saline-treated animals, whereas the effect was not 
significant in burned skin between treatments. Histological analysis revealed that 
antagonist-treated wounds showed evidence of decreased wound contraction 
which may indicate improved scar resolution and decreased risk of fibrosis. 
Interestingly, the gene expression results in many ways parallel those seen in 
foetal skin, which after injury, heals without scar. These results warrant further 
study into the subject area, especially to observe whether further improvements 
can be made by adjusting the treatment regimen. 
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1 LITERATURE REVIEW 
Introduction 
Wound healing and treatments for improving wound healing in skin have been 
studied since ancient times. Currently, the basic molecular pathways and 
biological processes of wound healing are well understood and are categorised 
by four overlapping phases: hemostasis, inflammation, proliferation and tissue 
remodelling. The final phase is characterised by scar formation, which, if not 
coordinated properly, can lead to pathological conditions such as keloids or 
hypertrophic scar, not to mention loss of skin function and disfigurement. To 
understand the principles of healing in skin it is necessary to understand the 
biological elements of skin. This review will outline the structure and 
developmental origin of skin, the phases of wound healing and the various key 
growth factors and cytokines involved, as well as a review of research that has 
attempted to intervene in the healing process to make improvements, or restore 
normal healing. This information will provide an important backdrop in anticipation 
of the objectives this study has been designed to achieve. 
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1.1 Skin: Structure and Function. 
The skin is the largest organ in the human body and serves many essential 
physiological functions. These include: regulating body temperature; providing a 
protective barrier against the outside environment and its microbial threats; 
detecting sensations relating to touch, pressure, temperature, and pain; excreting 
water, ions, organic compounds, and heat; accomodating important immune 
cells; acting as a reservoir for blood, especially during exercise; and synthesising 
Vitamin D (Montagna 1986; Tortora and Grabowski 1996). Structurally, there are 
two main parts: the thin outer layer known as the epidermis, which overlays the 
thicker, connective tissue-rich dermis (Figure 1.1). The boundary between the 
dermis and subcutaneous tissue is not discrete and each extends into the other 
so that the skin remains anchored to the rest of the body. The skin must be highly 
flexible to adapt to every movement of the body and yet rigid enough to maintain 
form and function. 
 
 
 
Figure 1.1: Structure of the skin and underlying subcutaneous tissue 
(Adapted from Tortora and Grabowski 1996) 
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1.1.1 The epidermis 
Keratinocyte stratification 
The epidermis comprises the interfollicular epidermis with its adjacent structures, 
including the sebaceous glands and the hair follicles (Watt et al. 2006). The 
epidermis usually consists of four layers, each containing a group of 
keratinocytes at different stages of development (Figure 1.2). The one-cell-deep 
basal layer in contact with the dermis is termed the stratum basale or stratum 
germinativum (Montagna and Parakkal 1974). This layer contains a continuum of 
three types of cells: stem cells (Figure 1.3), transit-amplifying cells which have 
undergone a few rounds of division (Watt et al. 2006), and committed cells (Jones 
et al. 1995). Only cells of the basal layer are mitotically active and, as they leave 
the basal layer and push outward toward the skin surface, they withdraw from the 
cell cycle and become terminally differentiated (Blanpain and Fuchs 2006; Fuchs 
and Horsley 2008).  
 
 
 
 
Figure 1.2: Epidermal layers 
Epidermal cell types overlaying basement membrane showing keratin filament 
bundles and intercellular junctions (desmosomes) (modified from Fuchs 2008). 
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The next stratum is an 8-10 cell layer consisting of many-sided cells welded 
together at junctions known as desmosomes (Tortora and Grabowski 1996). This 
is the stratum spinosum and is where the process of keratinisation begins (Smith 
and Dale 1986). The next layer is the stratum granulosum which is a granular 
layer containing various sized keratohyalin (the precursor of keratin) granules 
(Montagna and Parakkal 1974). About 90% of epidermal cells are keratin-
producing keratinocytes. Keratin provides waterproofing and protection from light, 
heat, microbes and many chemicals (Tortora and Grabowski 1996). Cells in the 
stratum granulosum show various levels of transcriptional activity (Blanpain and 
Fuchs 2006), as their nuclei are at various stages of degeneration (Tortora and 
Grabowski 1996). 
 
The last and outermost layer is called the stratum corneum. It consists of dead, 
flattened keratin-filled cells which are regularly shed and replaced by those 
coming up from underneath. The life span of a keratinocyte is about 4 weeks 
(Fuchs 2007) from basal stem cell to enucleated, cornified, dead keratinocyte. 
These dead skin cells, also known as squames, are eventually sloughed off. In 
certain hairless areas of the body where the epidermis is quite thick, for example, 
the palms of the hands and soles of the feet, there is a fifth layer between the 
stratum granulosum and the outermost stratum corneum called the stratum 
lucidum. This layer contains three to five layers of dead cells which enclose 
droplets of eleidin, a substance which eventually becomes keratin (Tortora and 
Grabowski 1996). 
Other cells of the epidermis 
Aside from keratinocytes and the various forms they take, there are other specific 
cell types contained within the epidermis. Almost a tenth of the epidermal cells 
are melanin-producing melanocytes. These cells have long slender projections, 
which transfer granules of melanin to keratinocytes. This functions to shield the 
nucleus on the inner side from mutagenic UV light (Tortora and Grabowski 1996). 
Melanogenesis is thought to be stimulated by DNA photodamage and its repair 
(Young and Agar 2005). Another type of cell known as Langerhans cells are 
considered to be immigrants to the epidermis but their exact origin is 
controversial. They are dendritic cells originally described as bone marrow-
derived, antigen-presenting cells (Steinman and Cohn 1973). They are therefore 
an important member of the immune system and constitute the first 
immunological barrier against pathogenic threats from the outside environment 
(Merad et al. 2002). Recent research suggests that under normal conditions, 
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turnover of Langerhans cells is accounted for by the rate of division of 
Langerhans cells in the epidermis. However, when Langerhans cells become 
depleted, for example, by exposure to UV light (to which they are very sensitive), 
replacements are derived from either the hair follicle, which is a reservoir for 
epidermal Langerhans cells (Gilliam et al. 1998), or from blood-borne precursors 
known as monocytes, which respond to chemokine attractants expressed by 
keratinocytes (Merad et al. 2002; Ginhoux et al. 2006). A fourth type of cell is 
found in the basal layer, attached to keratinocytes in thickened regions of the 
epidermis known as tactile discs (Montagna and Parakkal 1974). Named Merkel 
cells, they are associated with touch sensation. They contain granules which 
enclose neuropeptides thought to work as neurotransmitters through which 
Merkel cells exert their effect on their associated sensory nerves (Moll et al. 
2005). 
 
 
Figure 1.3: Stem cell locations in mammalian epidermis 
There is strong evidence for the existence of stem cells in the hair follicle bulge 
(blue). It is unclear whether interfolicular epidermal (IFE) stem cells exist 
singularly or in clusters. There is potentially a third stem cell population in the 
sebaceous gland (red); however, it is also possible that the sebaceous gland is 
maintained by bulge stem cells. Abbreviations: DP, dermal papilla; HF, hair 
follicle; IFE, interfollicular epidermis; SG, sebaceous gland (modified from Watt et 
al. 2006). 
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1.1.2 The dermis 
General structure 
The dermis provides the overall structure of the skin. It offers strength and 
flexibility via its extensible and elastic properties. Its texture varies depending on 
the area of the body.It is thin and flexible over joints, yet very thick and tough on 
the back (Vines 1995). Its primary constituent is known as extracellular matrix 
(ECM), which provides structural support and a surface for the body‘s cells to 
attach. ECM is composed of a loosely arranged mass of randomly oriented 
connective tissue fibres set in an unstructured gel-like ground substance. The 
fibrous connective tissue proteins (collagen and elastin) provide the tensile 
strength and elastic properties of the ECM. The upper portion of the dermis is 
known as the papillary region which is characterised by small, often vascularised 
and innervated, finger-like projections. These projections greatly increase the 
surface area of the basement membrane separating the dermis from the 
epidermis, aiding delivery of nutrients to the non-vascular epidermis (Tortora and 
Grabowski 1996). These projections in the papillary dermis known as dermal 
papillae should not be confused with dermal papilla cells at the base of the hair 
follicle (see Section 1.2.3 Hair follicle morphogenesis) 
 
Figure 1.4: Divisions of the dermis. 
Papillary and reticular regions of the dermis are separated by the rete 
subpapillare. Scale bar = 46 µm (from Sorrell and Caplan 2004). 
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The reticular region of the dermis is separated from the papillary dermis by a 
vascular plexus called the rete subpapillare (Sorrell and Caplan 2004) (see 
Figure 1.4 and Figure 1.5). While the reticular dermis is dense in connective 
tissue, there are spaces which are occupied by hair follicles, nerves, oil glands, 
sweat glands, and some adipose tissue (Tortora and Grabowski 1996). 
Extracellular matrix (ECM) 
Collagens and Elastin 
While many different keratins dominate in the ever-renewing epidermis, collagens 
dominate the dermis. Collagens and other structural compoments of the ECM are 
secreted by dermal fibroblasts. Collagen is the most abundant protein in the 
mammalian body and many authors cite that it constitutes three quarters of total 
protein in skin. Collagens are glycoproteins which exist in at least 26 distinct 
forms (Alberts et al. 2002), but the primary two in the dermis are type I (80–85%) 
and type III (8–11%) collagens (Schultz et al. 2005). Collagen type I fibrils (75 nm 
diameter) are organised into bundles of thick fibres varying in diameter (2–10 µm), 
their main function being resistance to tension. Conversely, collagen type III fibrils 
(45 nm in diameter) exist as loosely packed fibres of more uniform diameter (0.5–
1.5 µm), which form a mesh network maintaining the elastic property of skin and 
expansible organs (Montes 1996). Mutations affecting type I collagen cause 
Osteogenesis Imperfecta, wherein bones are weak and fracture easily. Mutations 
affecting type III collagen cause Ehlers-Danlos syndrome, characterised by 
fragile skin and blood vessels (Alberts et al. 2002).  
 
Elastin is an extremely durable, insoluble biopolymer which exhibits little turn-
over in healthy tissue (Mithieux and Weiss 2005). It comprises only a small 
proportion of normal human skin (2-4% dry weight) but several cutaneous 
diseases reveal the important structural role played by elastic fibres (Uitto 2008). 
A network of elastic fibres (consisting of 90% elastin) in the ECM gives skin the 
required resilience so that it can recoil after stretch (Mithieux and Weiss 2005). 
Collagen fibrils are entwined with elastic fibres to limit the extent of stretching and 
avoid tissue rupture (Alberts et al. 2002). 
Fibronectin and Laminin 
The remaining fibrous glycoproteins of the dermis include fibronectin and laminin. 
Fibronectin has many different types of binding sites allowing it to link together 
different types of ECM cells and molecules. For example, when fibronectin 
molecules bind to integrin receptors on cells, signalling pathways that promote 
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cell attachment, migration and differentiation are stimulated (Schultz et al. 2005). 
Laminin is the fundamental protein of the basal lamina, also known as the 
basement membrane. The basement membrane constitutes sheets of laminin 
with a layer of specialised anchoring fibrils made of type VII collagen molecules, 
which tether it to the underlying connective tissue (Alberts et al. 2002). It takes 
this sheet-like form in almost every animal tissue (Colognato and Yurchenco 
2000). In the case of skin, epidermal cells rest on the basement membrane which 
separates the dermis and epidermis. The basement membrane is rich in tyrosine 
kinase growth factors; these stimulate proliferation in the basal layer of the 
epidermis (Fuchs and Horsley 2008). 
Proteoglycans and glycosaminoglycans 
The other main class of extracellular macromolecules are polysaccharide chains 
of the group called glycosaminoglycans (GAGs) (Alberts et al. 2002). These are 
usually found covalently linked to a core protein in the form of proteoglycans, 
which can have one or more GAGs attached. Proteoglycans possess a diverse 
array of abilities, and knockout studies have shown some to be essential to life 
(Iozzo 1998). They are known as tissue organisers for their influence on cell 
growth and the maturation of specialised tissues by modulating growth factor 
activities. They also act as biological filters and regulators of collagen 
fibrillogenesis, determining skin tensile strength (Iozzo 1998). GAGs are strongly 
hydrophilic. Their strong negative charge (owing to sulfate and carboxyl groups) 
attracts osmotically active Na+, causing large amounts of water to be drawn into 
their structure (Chakravarti et al. 1998; Schultz et al. 2005).This creates the gel-
like consistency which pervades the extracellular spaces providing a turgor 
pressure, enabling the matrix to withstand compressive forces (in contrast to 
collagen fibrils, which resist stretching) (Alberts et al. 2002). Several different 
species of GAG have been described: chondroitin sulfate, dermatan sulfate, 
keratin sulfate, heparin sulfate, and hyaluronate (this is non-sulfated and not 
found as a proteoglycan) (Montagna and Parakkal 1974). 
Dermal cells 
Fibroblasts 
The dominant cell type in the dermis is the fibroblast. Fibroblasts are the cells 
responsible for secreting most of the ECM components. Fibroblasts are present 
in various connective tissues and represent a heterogeneous population of cells. 
However, there seems to be no formal classification to define fibroblast 
subphenotypes (Darby and Hewitson 2007; Rinn et al. 2008). A large-scale gene 
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expression study of human fibroblasts has revealed strikingly distinct patterns of 
gene expression for fibroblasts from several different anatomical sites, but which 
were morphologically similar. It was discovered that the diversity of fibroblasts 
from multiple sites within an individual subject was greater than the diversity of 
fibroblasts at the same anatomical site between individuals (Rinn et al. 2008). 
Fibroblasts also retain a positional memory when removed (Chang et al. 2002; 
Rinn et al. 2008), and this is likely to be important in determining the 
developmental programs of various structures and organs in the body. 
Fibroblasts present in many tissues are normally in a relatively quiescent state 
(Darby and Hewitson 2007). The slow, continuous turnover of matrix 
macromolecules aids cell migration, where matrix metalloproteases and serine 
proteases cooperate to degrade matrix proteins such as collagen, laminin, and 
fibronectin (Alberts et al. 2002). Fibroblasts also help to organise the matrix: they 
crawl over it and pull on the collagen they have secreted, helping to compact it 
into sheets and draw it out into cables (Alberts et al. 2002). Normal adult human 
skin contains at least three distinct subpopulations of fibroblasts. They are: 
papillary dermal fibroblasts, which reside in the superficial dermis; reticular 
fibroblasts, which reside in the deep dermis; and fibroblasts associated with hair 
follicles (Sorrell and Caplan 2004). A few specialised types of fibroblasts are 
known such as osteoblasts in bone, chondroblasts in cartilage, and 
myofibroblasts in regenerating soft tissue. Fibroblasts are crucial during 
cutaneous wound repair and will be discussed further in this review (see 
Fibroplasia, in Section 1.3.3 below) 
Other dermal cells 
Other cells of the dermis include macrophages, mast cells, adipocytes and 
endothelial cells. Macrophages and mast cells play key roles in the immune 
system response and are derived from bone marrow and blood-borne precursors 
known as monocytes. Macrophages are known as scavengers because of their 
phagocytic capability in dealing with cellular debris. They are important in the 
inflammatory response, but are suggested to be involved in numerous other 
metabolic and immunological processes (Makoto 2008). They have also been 
observed in the dermis at all stages of prenatal development (Van Exan and 
Hardy 1984). Skin mast cells are best known for their often detrimental role in 
allergic responses. However, this view is changing and mast cells are now 
appreciated for their physiologic roles in skin, where their ability to sense a wide 
range of danger signals suggests they are important players in innate immunity 
(Metz et al. 2008). Mast cells contain heparin, a natural anti-coagulant, and 
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histamine, a vasodilator. Adipocytes and endothelial cells, with their associated 
pericytes (Armulik et al. 2005) (see Endothelial migration, Section 1.3.3), develop 
to form adipose tissue and blood vessels, respectively, in the lower dermis 
extending into the hypodermis. 
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Figure 1.5: Summary diagram for the structure and main cell types of the skin 
(Adapted from Alberts et al. 2002). 
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1.2 Developmental Origin of Skin and its 
Structures 
A few days after implantation, the inner cell mass of the blastocyst begins to 
differentiate into the three primary germ layers (Tortora and Grabowski 1996). 
These are termed ectoderm, mesoderm and endoderm by way of their positional 
relationship to each other. Shortly after gastrulation, the single layer of 
neuroectoderm cells that remain at the embryo surface will ultimately become the 
nervous system and skin epidermis. Here, Wnt signalling blocks the effect of 
fibroblast growth factors (FGFs) causing the cells to express bone morphogenetic 
proteins (BMPs), and therefore, develop into epidermis (Fuchs 2007). The single 
layer of ectoderm becomes two-layered with the formation of the protective 
periderm (Cui et al. 2007) over a single layer of multipotent epithelial cells (Fuchs 
2007). The periderm undergoes further stratification to form intermediate layers at 
about the time that appendages begin to appear (Polakowska et al. 1994). The 
transient periderm is destined to be sloughed into the amniotic fluid and 
eventually replaced by the first fully keratinised epidermal cells that move up from 
the basal layer at later stages of development (Polakowska et al. 1994). As 
development continues, from the original layer of multipotent epithelial cells, a 
stratified epidermis, hair follicles, sebaceous glands, and sweat glands form 
(Blanpain and Fuchs 2006). All epidermal layers are present by the fourth month 
of foetal development in humans (Tortora and Grabowski 1996).  
1.2.1 Dermal – epidermal interactions during development 
Cells of the dermis derive from the somite mesoderm. Signalling from specialised 
mesenchymal cells within the dermis coordinates the decision to form hair 
follicles or sweat glands (Millar 2002; Fuchs and Horsley 2008). This has been 
demonstrated elegantly by several studies which place ectopic epithelial tissue 
over native mesenchyme, causing native epithelial structures to develop in most 
cases (Montagna and Parakkal 1974; Hardy 1992; Koster and Roop 2007; Rinn 
et al. 2008). The reverse is also true, as shown in a study in which dermal-sheath 
tissue from the scalp of an adult human male was implanted into the forearm of a 
genetically unrelated female. This was sufficient to form new dermal papillae and 
induce new hair follicles of a larger, thicker and mostly pigmented form more like 
the donor‘s scalp and not at all like the small un-pigmented hairs of the recipient‘s 
forearm (Reynolds et al. 1999). These studies show that the process of 
appendage development seems to be characterised by an initial signal from the 
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dermis to the epidermis with instructions to make an appendage. After this 
initiating signal, the epidermis replies with a chemical message of its own to 
which the dermis reciprocates with more specific instructions as to what the 
epidermis is to do next (Hardy 1992; Millar 2002) (see Figure 1.6 and Section 
1.2.3 below). 
 
 
 
Figure 1.6: Dermal to epidermal communication during development 
(From Hardy 1992). 
 
Epidermis, hair follicles and sebaceous glands all have distinct stem cells which 
can self-renew, fully generate their respective tissues, and maintain homeostasis 
once the tissue is formed (Fuchs and Horsley 2008). 
1.2.2 Epidermis morphogenesis 
Epidermal morphogenesis begins in the basal layer, which maintains a stem cell 
population that gives rise to the more differentiated keratinocytes in higher levels 
of the stratified epidermis (see Keratinocyte stratification in Section 1.1.1). The 
basal layer produces, secretes, and assembles a type of extracellular matrix, 
comprising most of the basement membrane separating the epidermis and the 
dermis (Blanpain and Fuchs 2006). The basement membrane, upon which the 
basal layer rests, is rich in proteoglycans and other proteins that act as ‗molecular 
sinks‘ for growth factors which restrict (Transforming Growth Factor (TGF)-βs) or 
promote (TGF-α, Epidermal Growth Factor (EGF), Insulin-like Growth Factors 
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(IGFs)) epidermal proliferation (Fuchs 2008). In the life of an organism, there 
must be a continuous supply of differentiated keratinocytes from the basal layer, 
as all are eventually sloughed off. Therefore, basal keratinocytes must repress 
the expression of genes that initiate terminal differentiation to prevent this 
differentiation occurring prematurely, while also maintaining the expression of 
genes required for proliferation (Koster and Roop 2007). The protective and anti-
dehydration qualities of the epidermis are found in the properties of keratin. 
Keratins constitute up to 85% of a fully differentiated keratinocyte and keratin 
filaments are among the most stable found in nature (Fuchs 1995). Typically, the 
basal layer expresses keratins K5 and K14, whereas the intermediate suprabasal 
layers express K1 and K10 (Fuchs 1995; Blanpain and Fuchs 2006; Fuchs 2007). 
K6, K16 and K17 are also expressed suprabasally, but only in hyper-proliferative 
situations such as wound healing (Fuchs 2007). Epidermal growth and 
proliferation is in constant balance: if there is too little proliferation, the result will 
be thinning of the skin, thus compromising protection (Fuchs 2007), while too 
much can result in hyper-proliferative disorders, including psoriasis (Lowes et al. 
2007) and cancers. 
 
Mesoderm-derived cells contribute to the collagen-secreting fibroblasts of the 
underlying dermis (Montagna and Parakkal 1974), blood vessels, arrector pili 
muscles that attach to each hair follicle, subcutaneous fat cells, and the immune 
cells that infiltrate and reside in the skin (Blanpain and Fuchs 2006). Neural crest–
derived cells contribute to melanocytes, sensory nerve endings of the skin, and 
the dermis of the head (Blanpain and Fuchs 2006). Two main types of dermis are 
present at the onset of skin morphogenesis: a superficial dense dermis and a 
superficial loose dermis, which will form future hair and bare skin regions 
respectively (Olivera-Marinez et al. 2004). 
1.2.3 Hair follicle morphogenesis 
As alluded to earlier, hair follicle formation occurs during embryogenesis with a 
series of signals sent between dermal cells and overlying epithelial cells on the 
surface, causing fate changes in both cell populations (Millar 2002). An initial 
signal originating in the dermis (1st dermal message) triggers the formation of 
regularly spaced thickenings in the epidermis, known as placodes (Hardy 1992; 
Millar 2002). As dermal cells populate the skin, they receive signals from the 
epithelium (epidermal message) to form ‗dermal condensates‘, which are the 
precursors to dermal papilla (DP) cells (Fuchs 2008). Signalling candidates for 
this phase include Wnt family and platelet-derived growth factor (PDGF)-A 
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pathways (Millar 2002). The diversity of human dermal fibroblasts likely has 
connection with anatomic patterning of skin also (Rinn et al. 2008), and this is 
expected to contribute to the remarkable diversity of its structure and function. 
Following another signal (2nd dermal message) from the dermal condensate, the 
epithelial placode cells proliferate, down-grow, and invade the dermis, 
surrounding the dermal condensate, which becomes the dermal papilla of the hair 
follicle (Hardy 1992; Millar 2002). Sonic Hedgehog (involved in embryonic 
patterning of organs and nervous system) when expressed in the placode is a 
key player in follicle morphogenesis, together with Wnt (also involved with 
embryonic morphogenesis) and the BMP inhibitor Noggin (Fuchs 2008). These 
factors are required to form the DP from the dermal condensate (St-Jacques et al. 
1998; Millar 2002; Levy et al. 2005). Lymphoid enhancer-binding factor-1 (LEF1) 
and stabilised β-catenin are also critical for hair follicle morphogenesis (Fuchs 
2008; Fuchs and Horsley 2008) in humans. The down-growing epidermal cells 
become known as the hair matrix, whose daughter cells then move up the follicle, 
differentiating into either hair cells or inner root sheath (IRS) cells, depending 
upon their position (Hardy 1992). The outer layer of cells becomes the outer root 
sheath (ORS), which runs contiguous with the basal epidermis and is enclosed 
on its exterior by the basement membrane (Blanpain and Fuchs 2006). Notch-1 
expression is a key factor for controlling the phenotype of keratinocytes as they 
leave the matrix and differentiate into the particular cell lineages of the hair follicle 
(Millar 2002). The final result of this process is a keratinised hair (see Figure 1.7). 
 
Figure 1.7: Embryonic stages of hair follicle morphogenesis 
(From Fuchs 2008). 
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1.2.4 Sebaceous gland development 
Sebaceous glands are usually located attached to the follicle above the bulge and 
arrector pili muscle, just below the skin surface. Together with the follicle, the 
sebaceous gland is known as the pilosebaceous unit. They are found all over the 
body except on the palms of hands or soles of the feet (Smith and Thiboutot 
2008). Until recently, relatively little was known about its function as it was 
considered an evolutionary vestige. However, today there are at least 30 specific 
functions under investigation by various researchers (Zouboulis et al. 2008). 
Broadly speaking, the sebaceous gland produces lipids and sebum for lubrication 
and protection against bacteria. It does this via the production of terminally 
differentiated sebocytes, which disintegrate to release their oils in a holocrine 
manner (Fuchs 2007; Fuchs 2008; Smith and Thiboutot 2008). The sebaceous 
gland remains attached to, and develops alongside, the developing hair follicle, 
where at least three important pathways are involved: the Wnt signalling pathway, 
the c-myc signalling pathway, and the hedgehog signalling pathway (Smith and 
Thiboutot 2008).  
1.2.5 Sweat gland development 
During the third month of human embryonic development, epidermal ridges form 
on the palms, fingers, and soles of feet. Epidermal or ‗rete‘ ridges occur because 
the undulating contour of the dermis-epidermis boundary (with underlying dermal 
papillae) is more pronounced in these areas (Jones et al. 1995; Tortora and 
Grabowski 1996; Blanpain and Fuchs 2006). About the same time, sweat glands 
begin to develop as a cord of epithelial cells growing from the epidermal ridge on 
the palms, fingers, and soles, and by the fifth month on the rest of the body (Sato 
et al. 1989 cited in; Morimoto and Saga 1995; and Saga 2002). The human body 
has 3-4 million sweat glands, of which there are two types: eccrine and apocrine 
sweat glands (Morimoto and Saga 1995; Saga 2002). Eccrine sweat glands cover 
almost the entire body surface with ducts that open directly to the skin surface, 
whereas apocrine glands exist mainly in the axillary and genital areas with ducts 
opening to hair follicles (Morimoto and Saga 1995; Saga 2002) The main function 
of eccrine glands is the control of body temperature. Humans have a unique 
ability to dissipate heat faster than any other animal (Quinton 1983). The 
secretory portion of the sweat gland derives from embryonic epidermal tissue 
which differentiates into three types of cells: clear secretory cells (rich in sodium-
potassium-chloride [Na+-K+-2Cl-] co-transporters), dark secretory cells (which 
contain glycoprotein granules), and myoepithelial cells (for gland contraction) 
(Morimoto and Saga 1995; Saga 2002; Kreyden and Scheidegger 2004). 
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In summary, the epidermis and dermis derive from epithelial and mesenchymal 
progenitor tissues respectively. These tissues themselves arise from different 
embryonic sources; the epidermis from ectoderm and the dermis from 
mesodermal provenance. These tissues, with their respective gene expression 
programmes, interact and orchestrate the development of the skin and its 
structures in a highly coordinated manner. Any failure to properly develop either 
the dermis or the epidermis will almost certainly result in noticeable defects in 
appendage development. 
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1.3 Wound Healing 
Tissue disruption in higher vertebrates, unlike lower vertebrates, results not in 
regeneration, but in a rapid repair process (Wahl 2002; Eming et al. 2007b) 
involving bleeding, inflammation, proliferation (which includes re-epithelialisation, 
angiogenesis, and fibroplasia), and the formation and maturation of a scar (tissue 
remodelling) (Yamaguchi and Yoshikawa 2001; Chodorowska and Rogus-
Skorupska 2004; Diegelmann and Evans 2004; Watson 2006; Eming et al. 
2007b). Numerous cell signalling events involving various cytokines and growth 
factors coordinate this extremely complex process (Li et al. 2007). 
1.3.1 Healing Phase I - Hemostasis 
The shortest in duration yet most critical phase in healing is hemostasis. Injury to 
any vascularised tissue, whether internal or external, will cause some blood loss. 
Therefore, immediately following injury, minimising blood loss is the primary goal. 
Hemostasis involves two major processes: development of a fibrin clot and 
coagulation (Li et al. 2007) which are carefully directed by a series of important 
cytokines and growth factors (Table 1.1).  
Fibrin clot 
Platelets accumulate at the injury site by a process involving activation, adhesion, 
and aggregation to form a tightly-packed plug, which is the first step in 
hemostasis (Li et al. 2007; Nurden 2007). As blood components escape and leak 
into the injury site, platelets come into contact with, and are activated by, exposed 
collagen and other ECM components. Platelets have a series of surface 
membrane glycoproteins that allow adhesion to collagen (Nurden 2007), 
fibronectin and other adhesive proteins (Li et al. 2007). Upon contact, platelets 
release clotting factors, essential growth factors and cytokines such as TGF-β 
and platelet-derived growth factor (PDGF) (Singer and Clark 1999; Yamaguchi 
and Yoshikawa 2001; Diegelmann and Evans 2004; Metcalfe and Ferguson 
2007; Hantash et al. 2008). Platelets also release substances that promote 
angiogenesis, inflammation, and the immune response (Nurden et al. 2008). 
When integrin αIIbβ3 becomes activated and binds fibrinogen (cleaved by 
thrombin (Martin 1997)), and other adhesive proteins form bridges between 
platelets (Nurden 2007; Nurden et al. 2008), aggregation occurs and this 
stabilises the plug (Laurens et al. 2006).  
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Coagulation 
Coagulation is a very complex process involving a couple of different cascades 
(coagulation and complement cascades), which entails a number of proenzyme-
to-activated-enzyme conversions resulting in the transformation of prothrombin 
into thrombin, which in turn converts soluble fibrinogen into insoluble fibrin 
(Lorenz and Longaker 2003; Li et al. 2007). The end result is a provisional matrix 
of platelets embedded in a mesh of cross-linked fibrin fibres over and through 
which cells such as leukocytes, keratinocytes, fibroblasts, and endothelial cells 
can migrate (Martin 1997; Li et al. 2007). The clot also functions as a reservoir of 
growth factors and cytokines released by degranulating platelets, which will be 
involved in all phases of wound healing, such as attracting circulating 
inflammatory cells, contributing to the process of re-epithelialisation and wound 
contraction, and stimulating the angiogenic response (Martin 1997; Baum and 
Arpey 2005; Li et al. 2007).  
 
Table 1.1: Key growth factors released during and shortly after hemostasis 
Growth factor Function 
PDGF Chemotaxis for macrophages and fibroblasts, 
macrophage activation, fibroblast mitogen and matrix 
production and angiogenesis (Yamaguchi and Yoshikawa 
2001). 
TGF-β Keratinocyte migration, chemotaxis for macrophages 
and fibroblasts, and fibroblast matrix synthesis and 
remodelling (Yamaguchi and Yoshikawa 2001). 
Chemotaxis of neutrophils and monocytes (Wahl 2002). 
EGF Keratinocyte migration and replication (Yamaguchi and 
Yoshikawa 2001). 
Vascular Endothelial 
Growth Factor (VEGF) 
A vascular permeability factor; influences the 
extravasation of plasma proteins to create a temporary 
support structure (Wahl 2002) to produce localised 
swelling (Chodorowska and Rogus-Skorupska 2004) bind 
fibrin and stimulate angiogenesis (Werner and Grose 
2003). 
Fibroblast Growth Factor-2 
(basic FGF) 
Binds fibrin and stimulates angiogenesis (Werner and 
Grose 2003) 
IGF-1 Binds fibrin and stimulates stromal cell function and 
proliferation (Werner and Grose 2003). 
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1.3.2 Healing Phase II - Inflammation 
On the surface, the signs of inflammation are redness, heat, swelling, and pain. 
Once bleeding has stopped, vasoconstriction ceases and vasodilation occurs in 
the capillaries allowing extravasation of serum proteins and inflammatory cells 
into the wound site - a highly orchestrated process involving the nervous system, 
cytokines, chemokines, and growth factors (Baum and Arpey 2005) (see Figure 
1.8). Vasodilation is promoted via by-production of bradykinin and vascular 
permeability factor in the ‗coagulation cascade‘ and C3a/C5z anaphylatoxin 
production in the ‗complementary cascade‘ (Lorenz and Longaker 2003). In 
response, resident mast cells produce a number of mediators which promote 
vasodilation including histamine (Lorenz and Longaker 2003; Baum and Arpey 
2005), as well as chemotactic agents for leukocytes such as Tumour Necrosis 
Factors (TNFs), proteases, leukotrienes, and Interleukins (IL) (Li et al. 2007). 
With the onset of vasodilation in the acute stages, polymorphonuclear cells 
(polymorphs) are the first to arrive at the scene of a cutaneous wound. They are 
recruited from circulating blood in response to molecular changes in the surface 
of endothelial cells lining the capillaries at the wound site (Martin 1997). As the 
name suggests, polymorphs are leukocytes which give the appearance of 
possessing a many-lobed nucleus. 
Neutrophils 
Neutrophils arrive at the wound site within minutes of injury and steadily increase 
in number to peak at 24-48 hours post-wounding in adult human tissue (Metcalfe 
and Ferguson 2007). Their primary roles are to sterilise the wounded area by 
ingesting foreign particles and bacteria (Singer and Clark 1999; Lorenz and 
Longaker 2003), and to release pro-inflammatory cytokines such as IL1α, IL1β, 
and TNF-α (Yamaguchi and Yoshikawa 2001; Baum and Arpey 2005). This 
activates growth factor expression in macrophages, keratinocytes, and fibroblasts 
(Hübner et al. 1996), and promotes diapedesis (movement of cells in to and out 
of circulating blood through vessel walls) (Eming et al. 2007b). Neutrophils also 
begin the process of debridement (removal of dead, damaged tissue) and 
phagocytosis of infectious agents by release of a large variety of antimicrobial 
host-defence peptides and proteases (Eming et al. 2007b; Steinstraesser et al. 
2008). Later in inflammation, provided infection doesn‘t occur, neutrophils decline 
in number; macrophages then dominate (Li et al. 2007). 
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Macrophages 
Macrophages scavenge and phagocytose any foreign bodies including expended 
neutrophils that have previously phagocytosed foreign elements (Singer and 
Clark 1999). They release a myriad of factors including TGF-α, TGF-β, IGF-1, 
FGF, PDGF, VEGF, HB-EGF (heparin binding EGF-like growth factor) with the 
latter four promoting angiogenesis (Yamaguchi and Yoshikawa 2001). Although 
polymorphonuclear cell infiltration peaks at 24-48 hours, much is accomplished 
by this time with early cleansing of wound the site from cellular debris, foreign 
particles and bacteria (Baum and Arpey 2005). The exit of polymorphonuclear 
cells is facilitated by apoptosis (Darby and Hewitson 2007), macrophage 
phagocytosis, and via sloughed eschar (scab) (Baum and Arpey 2005). From 
here, the intensity of inflammation begins to subside and monocytes replace 
polymorphs as the major infiltrating cell type, where they subsequently transform 
into macrophages (Lorenz and Longaker 2003; Diegelmann and Evans 2004; 
Baum and Arpey 2005; Faler et al. 2006; Darby and Hewitson 2007). These 
macrophages continue the phagocytotic and proinflammatory work of the 
previous cohort but also participate in a more complex role in wound healing, 
remaining at the site for longer (days to weeks) (Baum and Arpey 2005). 
Monocytes and activated macrophages can bind to the ECM via cell surface 
integrin receptors (Hantash et al. 2008). In addition, macrophages release 
digestive enzymes such as matrix metalloproteinases (MMPs) for ECM 
degradation and turnover (Faler et al. 2006). Macrophages are the primary cells 
responsible for the regulation of tissue repair, and as such secrete more than 20 
different cytokines and growth factors during the repair process (Lorenz and 
Longaker 2003). Several authors have reviewed the stimulatory effects of 
macrophages and their products on other cells. Some of these include: attracting 
fibroblasts to the wound site, for example, by release of PDGF, TGF-β 
(Diegelmann and Evans 2004), and fibronectin (Li et al. 2007); stimulating 
fibroblasts to produce collagen via FGF-2, IGF, and TGF-β (which also stimulates 
fibroblasts to differentiate into myofibroblasts); stimulating angiogenesis by 
release of FGF-2, VEGF-A, and TGF-β; and stimulating re-epithelialisation via 
release of TGF-α, FGF-2 and IGF-1 (Werner and Grose 2003; Baum and Arpey 
2005). Therefore, macrophages are crucial in the progression of wound healing 
from inflammation to repair. 
T-lymphocytes and Eosinophils 
T-lymphocytes play a significant regulatory role in wound healing. One of these 
roles in humans is to produce connective tissue growth factor (CTGF) which 
22 
 
stimulates fibroblasts to divide and produce ECM components such as collagen 
type I, fibronectin, and integrin α5 (Workalemahu et al. 2003). Eosinophils appear 
to have a role in wound healing by producing TGF-α which promotes re-
epithelialisation by keratinocytes (Baum and Arpey 2005).  
 
The final stages of inflammation usher in the onset of re-epithelialisation, which 
coincides with the migration of fibroblasts and endothelial cells, and the formation 
of granulation tissue (Metcalfe and Ferguson 2007). 
 
  
2
3
 
 
 
Figure 1.8: Inflammatory phase after approximately 3 days 
Growth factors and cytokines at play in the inflammatory phase with macrophages directing much of the traffic. Illustration has been 
modified from the original by Singer and Clark (1999) to incorporate recent findings. 
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1.3.3 Healing Phase III – Proliferation 
The proliferative phase is characterised by the formation of a new epithelium at 
the wound surface and granulation tissue deep in the wound (Chodorowska and 
Rogus-Skorupska 2004). It is orchestrated throughout by cytokines produced by 
platelets, macrophages, fibroblasts and keratinocytes. Re-epithelialisation, 
granulation tissue formation, and angiogenesis all occur simultaneously in the 
proliferative phase, but each is discussed individually below.  
Re-epithelialisation 
Within hours of wounding, the epidermis thickens and keratinocytes undergo 
morphological changes (Lorenz and Longaker 2003). Immature keratinocytes 
dissolve their attachment points (hemidesmosomes) to the basal membrane (via 
MMP-9 secretion which degrades collagen IV and laminins (Li et al. 2007)) and to 
each other (desmosomes) releasing themselves and migrating across the wound 
bed in response to chemo-attractants (Martin 1997; Singer and Clark 1999; Wahl 
2002). Leading-edge keratinocytes must express new integrins in order to grasp 
and crawl over the provisional wound matrix and underlying dermis (Martin 1997). 
Migration is aided by adhesion glycoproteins such as tenascin and fibronectin 
which act like ‗railroad tracks‘ (Lorenz and Longaker 2003). Migrating cells 
originate from the basal layer, from suprabasal cells, or a large contribution may 
come from stumps of hair follicles left intact after wounding (Martin 1997; 
Yamaguchi and Yoshikawa 2001; Ito and Cotsarelis 2008). It has been 
demonstrated that stem cells extracted from the hair follicle bulge can be induced 
to differentiate into hair follicle and sebaceous cells, which supports the 
multipotential capacity of cutaneous stem cells (Roh and Lyle 2006). In order to 
cut a path along the wound margin between the fibrin clot and healthy dermis, the 
leading-edge kerotinocytes must dissolve the fibrin barrier ahead of them (Martin 
1997; Baum and Arpey 2005). The activation of plasmin by plasminogen activator 
and the production of collagenases (MMPs) by epidermal cells dissolve fibrin and 
collagen type I, respectively (Yamaguchi and Yoshikawa 2001). An important 
characteristic of these keratinocytes is that they do not express functional 
fibrinogen/fibrin receptors such as the integrin αVbβ3 and therefore do not 
interact with, or become attached to, fibrinogen or its derivatives (Kubo et al. 
2001). Within two days after injury, epidermal cells at the wound margin begin to 
proliferate behind the migrating cells (Singer and Clark 1999). As re-
epithelialisation continues, basement membrane proteins reappear and 
epidermal cells revert to their normal phenotype (Singer and Clark 1999). Re-
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epithelialisation is usually complete within 24-48 hours (Baum and Arpey 2005). 
Following the establishment of a monolayer of keratinocytes, epidermal migration 
stops and a new stratified epidermis attached to the basal lamina re-emerges 
(Martin 1997; Lorenz and Longaker 2003) within 7-9 days (Li et al. 2007). Once 
the epithelial bridge is complete, enzymes are released to dissolve the 
attachment at the base of the scab (Diegelmann and Evans 2004), resulting in 
the dissection of the fibrin eschar from viable tissue (Singer and Clark 1999; 
Chodorowska and Rogus-Skorupska 2004). Important growth factors in the re-
epithelialisation process are EGF, TGF-α, and keratinocyte growth factor (KGF, 
also known as FGF-7) (Singer and Clark 1999; Chodorowska and Rogus-
Skorupska 2004).  
Granulation tissue 
Granulation tissue (named for the granular appearance of the blood vessels in 
the wound) is composed of inflammatory cells, fibroblasts, and newly-formed 
blood vessels (Wahl 2002) embedded in a loose ECM of collagen, fibronectin and 
hyaluronic acid (Chodorowska and Rogus-Skorupska 2004). Early in response to 
the injury, resident dermal fibroblasts near the wound begin to proliferate (Martin 
1997). The fibroblast front moves by chemotaxis into the wound led by a wave of 
phagocytosing macrophages (Thackham et al. 2008). Chemotactic agents 
include PDGF and TGF-β (Martin 1997). From here, fibroblasts become the 
dominant cell type in the wound area, with fibroplasia and angiogenesis ensuing 
(see Figure 1.9).  
Fibroplasia 
Fibroblasts produce an ECM which facilitates further cell migration and provides 
mechanical support for new capillaries, which in turn supply further nutrients to 
sustain cell metabolism (Gaffney et al. 2002). The main types of ECM 
components fibroblasts produce are collagens (mainly types I and III), fibronectin, 
elastin and proteoglycans. Collagens I and III are the major fibrillar collagens of 
the ECM in both wounded and unwounded skin (Lorenz and Longaker 2003). 
Type I collagen is the most abundant type of collagen in the normal dermis 
(approximately 80-90%) and type III collagen (normally 10-20%) is actively 
secreted by fibroblasts during the early stages of wound healing and may account 
for up to 30% of the collagen in a healing wound (Fathke et al. 2004; Kwon et al. 
2007). The marked increase in collagen III production after wounding may persist 
for several weeks (Robins et al. 2003) before normalising during the remodelling 
phase. Although collagen turnover naturally occurs continually in normal skin, 
collagen expression is suppressed in uninjured skin, supposedly for the benefit of 
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the healing wound (Ihlberg et al. 1993). Procollagens (precursor collagen 
polypeptides) are synthesised by fibroblasts. A critical step in their production is 
the hydroxylation of lysine and proline residues; this occurs in the endoplasmic 
reticulum and is important for the final arrangement of the precursor collagen 
molecules into mature triple-helix structures (Baum and Arpey 2005). Cross-
linking is another post-translational modification which takes both intramolecular 
and intermolecular forms as triple-helix molecules form fibrils and then fibres 
(Diegelmann 2001). Like keratinocytes, fibroblasts must also alter their integrin 
expression profile from collagen binding to fibrin, fibronectin and vitronectin 
binding receptors in order to crawl into the clot (Martin 1997). The fibronectin 
matrix also provides a scaffold for collagen fibrils (Li et al. 2007).  
 
The various roles played by fibroblasts in the process of wound healing are as 
important as they are diverse. In a microarray study of the transcriptional 
response of human fibroblasts to serum, Iyer et al. (1999) concluded that 
fibroblasts can participate in the processes of: hemostasis, clotting, clot 
dissolution, remodelling, chemotaxis and activation of neutrophils and T-
lymphocytes, angiogenesis, migration and proliferation of fibroblasts and their 
differentiation into myofibroblasts, and migration and proliferation of keratinocytes 
for re-epithelialisation. Fibroblasts also express receptors for a number of 
cytokines including PDGF, TGF-β1 and TNF-α which all may play a role in 
recruitment and activation during wound healing (Darby and Hewitson 2007). 
While fibroblasts can adequately produce and replace all ECM components of 
normal skin, a scar forms because their ability to organise those components is 
impaired (Singer and Clark 1999; Sorrell and Caplan 2004). Interestingly, elastin 
which is normally present in skin, is not produced in scars, and this may be a 
cause of the firmness and loss of flexibility seen in scar tissue (Baum and Arpey 
2005). 
Wound contraction 
As previously mentioned, fibroblasts can differentiate into myofibroblasts, which 
as the name suggests, endows them with a smooth muscle-like contractile ability. 
In fact, these specialised mesenchymal cells exhibit features of both fibroblasts 
and smooth muscle cells such as the expression of α-smooth muscle actin 
(Gabbiani 1992; Darby and Hewitson 2007). This ability appears to be important 
for wound contraction. Wound contraction decreases the size of the wound 
substantially (e.g. up to 80% in the trunk and perineum of humans), thus reducing 
the amount of new tissue formation needed (Lorenz and Longaker 2003). Re-
epithelialisation is also made easier by underlying contractile connective tissue, 
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as it brings wound margins closer together (Martin 1997). In mammals whose 
skin is loosely attached to the underlying tissue layer, for example: rodents, 
wound contraction results in wound closure with minimal scarring or loss of 
function, whereas in humans, whose skin is more firmly attached, contraction can 
be less beneficial, leading to outcomes that range from minor cosmetic scarring in 
some instances, to loss of joint motion or major body deformation in others 
(Grinnell 1994). Myofibroblasts also play a significant role in tissue fibrosis, with 
TGF-β implicated strongly as a mediator (Evans et al. 2003). Myofibroblasts are 
only transient in their presence at the proliferative phase, and as mechanical 
tension decreases they disappear by apoptosis (Grinnell et al. 1999).  
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Figure 1.9: Proliferative phase 
A: The temporary fibrin clot is infiltrated by inflammatory cells and fibroblasts as 
granulation tissue becomes densely packed with new capillaries. Granulation 
tissue contracts with the aid of myofibroblasts which tug on surrounding collagen 
fibres. B: Re-epithelialisation begins at the wound edge and from the remnants of 
hair follicles to re-establish the epidermal barrier. Leading edge keratinocytes 
clear a path over the provisional matrix and uninjured dermis (from Martin 1997). 
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Angiogenesis 
Angiogenesis is defined simply as the formation of blood vessels which sprout 
from existing blood vessels, while vasculogenesis specifically refers to the 
mobilisation of endothelial stem cells from bone marrow to form new blood 
vessels. Both processes occur together to produce new blood vessels in wound 
tissue (Eming et al. 2007a). Angiogenesis is necessary to nourish the newly-
formed granulation tissue (Singer and Clark 1999). Unique to wound 
angiogenesis, as opposed to other physiological and pathological conditions of 
vessel growth, is the involvement of the innate immune response. As mentioned 
previously, immediately following injury, different types of leukocytes are attracted 
to the injury site releasing an assortment of cytokines and growth factors, through 
which they may trigger, sustain or potentially terminate angiogenesis (Eming et 
al. 2007a).  
Cytokines and growth factors 
Several reviewers suggest that the most important factors in angiogenesis are 
VEGF, FGF-2, and TGF-β. These cytokines can be released by epidermal cells, 
fibroblasts, macrophages, and vascular endothelial cells (Diegelmann and Evans 
2004). Other growth factors known to enhance angiogenesis are PDGF, HB-EGF, 
IGF-1, hepatocyte growth factor (HGF) and FGF-2, along with heparin, leptin and 
fibronectin (Yamaguchi and Yoshikawa 2001), and also angiogenin, angiotropin 
and angiopoietin 1 (Singer and Clark 1999). VEGF can be detected at high levels 
during the proliferative phase, and its transcription is induced by PDGF, 
endothelial growth factor, TNF-α, TNF-β, interleukin-1β (IL-β), and exposure to 
hypoxia (Chodorowska and Rogus-Skorupska 2004). With the elevated metabolic 
activity at the wound site, there is elevated demand for oxygen and nutrients 
(Diegelmann and Evans 2004). Prolonged hypoxia seems to inhibit wound 
healing by blocking fibroblast proliferation, collagen production, and 
angiogenesis, as well as increasing the risk of infection (Thackham et al. 2008). 
However, the development of oxygen tension (Knighton et al. 1983), lactate build-
up (Zieker et al. 2008) and a low pH stimulates the release of factors which 
promote angiogenesis (Diegelmann and Evans 2004). An interesting signalling 
pathway involves the role of low oxygen tension, which in turn stimulates the 
expression of a nuclear transcription factor termed hypoxia-inducible factor-1 
(HIF-1) by vascular endothelial cells (Gerber et al. 1997). HIF-1 in turn binds as 
an enhancer to sequences of DNA that regulate the expression of VEGF, 
stimulating angiogenesis. With new blood vessels entering the wound repair 
area, the oxygen tension returns to a normal level. Oxygen then binds to HIF-1 
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and blocks its activity leading to a decrease in synthesis of VEGF (Diegelmann 
and Evans 2004).  
Endothelial migration 
The development of new blood vessels begins when MMPs are released into the 
connective tissue to clear the way for new capillaries to sprout. Fragments of the 
degraded proteins recruit blood monocytes to the site of injury and, following their 
conversion to macrophages, release angiogenic factors (Singer and Clark 1999). 
Macrophage-derived angiogenic factors affect endothelial cells mitogenically 
(FGF-2, TGF-α, IGF-1), or by inducing migration (angiotropin, human angiogenic 
factor), or are angiogenic by some other mechanism (Sunderkötter et al. 1991). 
Endothelial migration is also stimulated by the aforementioned important 
angiogenic factors (VEGF, FGF-2, and TGF-β). These factors also stimulate 
endothelial expression of integrins, especially αVbβ3 (Martin 1997; Baum and 
Arpey 2005), which bind ECM proteins to facilitate migration. The movement of 
endothelial cells towards their angiogenic stimulus requires the degradation of 
parent vessel basement membrane. This is achieved via FGF-2-stimulated 
conversion of plasminogen to plasmin and procollagenase to collagenase 
allowing these two proteases to digest basement membranes (Singer and Clark 
1999). Migrating endothelial cells then elongate and align with one another to 
create a solid sprout which increases in length as endothelial cells proliferate 
(Folkman and Klagsbrun 1987). Two capillary sprouts may join at their tips to 
form a loop allowing blood flow to begin, after which pericytes position 
themselves along the base of the loop and new sprouts grow from the apex of the 
loop to continue the angiogenic process (Folkman and Klagsbrun 1987).  
Extracellular matrix 
Aside from cells and cytokines, the structure and organisation of ECM 
components is important for angiogenesis. ECM components such as fibronectin, 
collagen and vitronectin provide structural support and guidance for invading 
capillaries and migrating cells as well as serving as a reservoir for important 
growth factors (Baum and Arpey 2005; Li et al. 2007). Laminins of the basement 
membrane have also been shown to be important for angiogenesis (Baum and 
Arpey 2005; Li et al. 2007). The transition of granulation tissue into scar tissue is 
represented by regression of capillaries no longer needed and differentiation of 
newly formed blood vessels into mature vascular structures (Eming et al. 2007a). 
Involution of newly-formed capillaries is achieved by endothelial apoptosis 
(Desmoulire et al. 1995; Lokmic et al. 2006). Several mechanisms have been 
identified which might contribute to vascular regression at the wound site: (i) 
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decreased expression of growth factors necessary for endothelial cell survival; (ii) 
increased expression of angiogenesis inhibitors; and (iii) the transition from a 
provisional pro-angiogenic ECM (consisting of vitronectin, fibronectin and fibrin) 
into a permanent collagenous ECM (Eming et al. 2007a). 
 
1.3.4 Healing Phase IV - Remodelling 
Upon completion of epithelialisation and fibroplasia, cell proliferation and 
neovascularisation cease, scar tissue forms, and the wound enters the 
remodelling phase, which continues for several months or even years. 
Remodelling is characterised by contraction, reduced redness, reduced 
thickness, and increased strength of the wound area (Baum and Arpey 2005). 
The central event in remodelling is the reorganisation of the collagen matrix in 
order to regain the former qualities of uninjured skin as much as possible. This 
event is characterised by a balance between synthesis of new components of the 
scar matrix and degradation by proteases (Eming et al. 2007a). The balance of 
newly-formed collagen with the destruction of old collagen determines the final 
physical quality of the scar (Metcalfe and Ferguson 2007). Degradation is driven 
by serine proteases and MMPs (also known as collagenases, gelatinases, and 
stromelysins) under the control of various cytokines (Wahl 2002). Tissue 
inhibitors of metalloproteinases (TIMPs) are natural inhibitors of MMPs (Birkedal-
Hansen 1995), and provide a counter-balance to degradation. Upsetting this 
balance can result in pathological wound healing states such as chronic ulcers. 
As remodelling progresses, the soft and gelatinous collagen type III laid down in 
the granulation phase is gradually replaced by more highly organised type I 
collagen (Chodorowska and Rogus-Skorupska 2004; Li et al. 2007), and there is 
a reduction in proteoglycan and water content (Baum and Arpey 2005). These 
events allow collagen fibres to lie closer together, allowing collagen cross-linking 
and ultimately decreasing scar thickness and increasing wound-bursting strength 
(Romo III et al. 2005). Collagen cross-linking is essential in providing tensile 
strength and mechanical stability of the collagen fibrils (Oxlund et al. 1996). The 
small leucine-rich proteoglycans (SLRPs) lumican and decorin modulate collagen 
fibrillogenesis and enhance collagen fibril stability (Neame et al. 2000). Wound 
strength remains inversely proportional to wound thickness over time (Baum and 
Arpey 2005). By day 21, new collagen production reaches a maximum and from 
this point on, fibroblasts gradually decrease production and begin to disappear 
(Baum and Arpey 2005; Li et al. 2007). At this point wound strength is only about 
20% that of normal skin, reflecting the haphazard arrangement of fibrils in the 
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dermis. However, the healed skin will reach a maximum strength of around 80% 
after 6 months as fibrils become more organised in line with directional stress 
forces on the skin (Baum and Arpey 2005). Regulation of collagen synthesis is 
controlled by several growth factors, of which TGF-β and FGF are the main ones 
(Li et al. 2007). The reduction in redness over time corresponds to the reduction 
in capillary density within the wound as it matures (Baum and Arpey 2005). 
Characteristic of mature scars is the absence of appendages such as hair 
follicles. Although keratinocyte stem cells easily repopulate the epidermis, stem 
cells responsible for appendages appear not to repopulate a scar (Baum and 
Arpey 2005). The formation of a scar may be seen as an unfortunate 
consequence of mammalian wound healing, but the benefit of scar formation is 
the prompt reformation of tissue integrity (Lorenz and Longaker 2003). 
 
1.3.5 Summary of wound healing events 
The phases of wound healing are by no means discrete and overlap 
considerably, as do the events within each phase. Figure 1.10 below illustrates 
this overlap and the roles of the various cell types within each phase at the 
wound site. Table 1.2 summarises the various key cytokines and growth factors 
present at the wound site including where they come from their target and their 
effect. It is interesting to note that many factors have autocrine and/or paracrine 
effects on the cells that secrete them. 
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Figure 1.10: Wound healing phases . 
 Generalised diagram of wound healing phases with key players and main events (modified from Li et al. 2007). 
Minutes Hours Days    Weeks   Months + 
 
Hours
 
Days 
 
 
 
Weeks
 
 
 
Month
s+ 
Hemostasis 
Inflammation 
Proliferation 
Remodelling 
  
3
4
 
Table 1.2: Summary of key growth factors present at the wound site 
Growth Factor Source Target cells Biological effect on target 
TGF-β1, TGF-β2 Macrophages, platelets, fibroblasts, 
keratinocytes 
Inflammatory cells, keratinocytes, fibroblasts Chemotaxis, proliferation, matrix production 
(fibrosis) 
TGF-β3 Macrophages Fibroblasts Anti-scarring? 
TGF-α Macrophages, platelets, keratinocytes Keratinocytes, fibroblasts, endothelial cells Proliferation 
TNF-α Neutrophils Macrophages, keratinocytes, fibroblasts Activation of growth factor expression 
PDGF Macrophage, platelets, fibroblasts, 
endothelial cells, vascular smooth muscle 
cells 
Neutrophils, macrophages, fibroblasts, 
endothelial cells, vascular smooth muscle cells 
Chemotaxis, proliferation, matrix production 
FGF-1, 2, 4 Macrophage, fibroblasts, endothelial cells Keratinocytes, fibroblasts, endothelial cells, 
chondrocytes 
Angiogenesis, proliferation, chemotaxis 
KGF (FGF-7) Fibroblasts Keratinocytes Proliferation, chemotaxis 
EGF Platelets, macrophages, keratinocytes Keratinocytes, fibroblasts, endothelial cells Proliferation, chemotaxis 
HB-EGF Macrophages, keratinocytes Keratinocytes, fibroblasts, smooth muscle cells Proliferation, chemotaxis (Raab and 
Klagsbrun 1997) 
IGF-1 Fibroblasts, macrophages, serum Fibroblasts, endothelial cells Proliferation, collagen synthesis 
IL-1α− and IL-1β Macrophages, neutrophils Macrophages, fibroblasts, keratinocytes Proliferation, collagenase synthesis, 
chemotaxis 
CTGF Fibroblasts, endothelial cells Fibroblasts Downstream of TGF-β1 
VEGF Macrophages, keratinocytes Endothelial cells Angiogenesis 
(from Lorenz and Longaker 2003 unless otherwise indicated). 
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1.4 Aspects of Wound Healing Research 
1.4.1 Factors affecting wound healing 
Stress, poor nutrition, and advancing age are the main factors that affect wound 
healing negatively. In addition, there are several local and systemic factors which 
contribute to delayed wound healing or lead to chronic wounds (Table 1.3) 
 
Table 1.3: Local and Systemic factors affecting wound healing 
(From Grey et al. 2006). 
1.4.2 Aberrant wound healing 
As outlined above, the process of wound healing is a highly complex and tightly 
controlled series of overlapping events facilitated by expression of myriad 
cytokines and growth factors at specific time points. The importance of these 
events and their regulation is revealed when the equilibrium of such aspects is 
upset and abnormal wound healing occurs. This may result in a deficiency of 
healing which manifests as an ulcer, or excessive healing resulting in fibrotic 
deformities such as keloids, hypertrophic scar and contracture. 
Local factors  Systemic factors 
Shock of any cause Advancing age and general immobility 
Inadequate blood supply Obesity 
Increased skin tension Smoking 
Poor surgical apposition Malnutrition 
Wound dehiscence (rupture) Deficiency of vitamins and trace elements 
Poor venous drainage Systemic malignancy and terminal illness 
Presence of foreign body and foreign body 
reactions 
Chemotherapy and radiotherapy 
Continued presence of micro-organisms Immunosuppressant drugs, 
corticosteroids, anticoagulants 
Infection Inherited neutrophil disorders, such as 
leucocyte adhesion deficiency 
Excess local mobility, such as over a joint Impaired macrophage activity 
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Deficient healing 
Ulcers (chronic inflammation),  
Ulcers are the most prevalent wound healing disorder in humans (Eming et al. 
2007b). Normal wound healing is characterised by the progression of the wound 
through 4 overlapping phases. However, chronic wound progression is not so 
orderly. Some areas of chronic wounds are found in different phases of the 
healing process, and keratinocytes at the wound edge have impaired ability to 
migrate (Li et al. 2007). Chronic inflammation is the chief characteristic of non-
healing ulcers (Eming et al. 2007b), and excessive infiltration of neutrophils is a 
significant biological marker of this (Diegelmann and Evans 2004). Excessive 
MMPs and elastase released by neutrophils as well as the presence of excessive 
reactive oxygen species contribute to further damage of cells and healing tissues 
(Diegelmann and Evans 2004). Sustained chronic inflammation leads to ECM 
collapse and formation of necrotic centres (Braiman-Wiksman et al. 2007). In 
chronic wounds there is also prolonged and increased T cell infiltration as well as 
increased macrophage number, without any evidence of increased autodigestion 
or phagocytosis (Loots et al. 1998).  
Excessive healing 
Fibrosis  
The goal of scar formation is to strengthen the affected area, although healed 
skin never totally regains normal tensile strength or function. Normally, wounds 
have stop signals which arrest the repair process when the wound is closed and 
re-epithelialisation is complete (Lorenz and Longaker 2003). Fibrosis is a 
pathological condition characterised by excessive matrix deposition and reduced 
remodelling (Diegelmann and Evans 2004), with major alterations in both the type 
and quantity of matrix synthesis (Darby and Hewitson 2007). Excessive scar 
tissue can lead to serious problems by impairing skin function, structure and 
aesthetic appearance in the area of the scarring (Eming et al. 2007b). In addition 
to disfigurement, severe burns can lead to scarring which restricts joint 
movement; this is known as contracture. Impaired bone growth can result from 
scar formation in juveniles after surgery, for example after the repair of cleft 
palates (Wilgus et al. 2003). Various fibrotic disorders can also result from 
abnormal (excessive) scar formation, and include hypertrophic scars (excessive 
collagen deposition within the original wound boundary) and keloids (excessive 
collagen deposition beyond the original wound boundary). Other fibrotic disorders 
include; tendon adhesions, transmission blockage of nerves, scleroderma, 
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Crohn‘s disease, oesophageal strictures, urethral strictures, liver cirrhosis, 
atherosclerosis and fibrotic non-union in bone (Diegelmann and Evans 2004). 
TGF-β is often cited as an inducer of fibrosis. A role for TGF-β1 in fibrogenesis 
has been theorised on the basis that TGF-β1 neutralising antibodies (Border et al. 
1990) and the natural TGF-β1-binding glycoprotein, decorin (Border et al. 1992), 
abolishes kidney fibrogenesis (Darby and Hewitson 2007). 
Keloids 
Keloids can be thought of as benign skin tumours which are common among 
people groups with darker pigmented skin (Bock et al. 2005; Köse and Waseem 
2008) presenting with autosomal dominance (Lorenz and Longaker 2003).Unlike 
hypertrophic scars, they grow invasively into surrounding healthy tissue beyond 
the original wound border (Bock et al. 2005). Keloids are relatively acellular in 
central regions, with fibroblasts present along their expanding borders where 
collagen deposition exceeds degradation (Lorenz and Longaker 2003). Keloids 
and other fibroproliferative disorders such as hypertrophic scarring (see next 
paragraph) present abnormalities in cell migration and proliferation, inflammation, 
synthesis and secretion of ECM proteins and cytokines, and wound remodelling 
(Singer and Clark 1999). In contrast to hypertrophic scar and normal skin, 
collagen fibrils of keloids appear thicker, more closely packed and more stretched 
(Tuan and Nichter 1998; Köse and Waseem 2008). Also in contrast to 
hypertrophic scars, the myofibroblast is absent from keloids, but energy demands 
are high, as indicated by the high level of adenosine triphosphate (ATP) 
expression (Köse and Waseem 2008). Keloid fibroblasts show increased 
expression of TGF-β1 and its type I receptor TβRI, but decreased expression of 
TGF-β3 (Bock et al. 2005). 
Hypertrophic scar 
It is difficult to distinguish between histological sections of keloids and 
hypertrophic scar under the microscope (Lorenz and Longaker 2003; Rekha 
2004). On the surface, hypertrophic scars present as red, raised, itchy, and 
inelastic (Scott et al. 1996). Burn injuries, traumatic injuries, and surgical 
procedures can give rise to exuberant scarring that results in permanent loss of 
function and/or disfigurement (Aarabi et al. 2007). Another possible contributor 
could be delayed or absent induction of apoptosis in myofibroblasts resulting in 
increased scarring (Darby and Hewitson 2007). Collagen bundles are fine and 
wavy, well-organised, and run parallel to the epidermis (Köse and Waseem 
2008). Wounds on their way to becoming hypertrophic do not demonstrate 
neovascular involution, but instead become increasingly vascular at this time 
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(Sheridan and Tompkins 2004). Compared to normal dermis or mature scar, 
hypertrophic scar tissue contains more water; probably a consequence of higher 
concentrations of GAGs (Sayani et al. 2000). 
Contracture 
Contractures are most likely to occur with severe burns where the severity of the 
scarring is proportional to the severity of the burn (Mahajan et al. 2006). 
Excessive wound contraction can lead to contracture, which distorts tissue and 
leads to impaired function. For example, wound contraction across a joint can 
result in a contracture leading to diminished range of motion and function of the 
joint (see Figure 1.11). Contractures can develop in the extremities, eyelids, neck, 
spine, and fingers (Lorenz and Longaker 2003). 
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Figure 1.11: Complications of scarring 
A: Typical hypertrophic scar. B: Contracture as a result of dermal scarring from a 
burn injury. C: Joint and bone deformation as a result of contracture, viewed 
under X-Ray (Aarabi et al. 2007) D: Keloid as a result of ear piercing (Wu et al. 
2006). E: Chest keloid on Japanese female. F: Extensive keloids on the trunk, 
neck, and arms of African American male (Marneros et al. 2004). 
 40 
 
1.4.3 Scarless wound healing 
Foetal wound healing 
It has been observed that mammalian foetal wounds heal without scarring or 
fibrosis, and that foetal wound healing is more like regeneration than repair. Scar-
free foetal wound healing occurs during the first one-third to one-half of gestation 
(Ferguson and O'Kane 2004) and is believed to heal via different mechanisms 
from adult healing, resulting in complete restoration of normal skin structure, with 
normal collagen deposition and regularly spaced hair follicles, capillaries and 
glands (Metcalfe and Ferguson 2007). One key difference between the healing of 
foetal and adult skin is the reduced level of inflammation after wounding in foetal 
wounds (Oberyszyn 2007), with lower numbers of, and less differentiated, 
inflammatory cells (Ferguson and O'Kane 2004). One theory for this is that adult 
wounds may be optimised for speed of healing in unfavourable conditions 
(bacteria, foreign bodies etc) which results in an excessive inflammatory cytokine 
profile, leading to scarring (Adzick and Lorenz 1994). Additional characteristics of 
foetal wound healing include rapid re-epithelialisation (Singer and Clark 1999), 
lack of fibrin clots and platelet degranulation, noticeably elevated levels of 
molecules involved in skin morphogenesis and growth (Metcalfe and Ferguson 
2007), and higher levels of hyaluronic acid (Ferguson and O'Kane 2004). These 
differences naturally reflect differences in the quality of the growth factor profile. 
Scar-free embronyic wounds show lower levels of TGF-β1, TGF-β2, and PDGF, 
and increased levels of TGF-β3 (Metcalfe and Ferguson 2007) in contrast to adult 
wounds (see Table 1.4 for a summary of the differences between adult and foetal 
wound healing). Interestingly, experiments conducted in mice, rats and pigs have 
mimicked foetal scar-free healing in adult tissues by neutralising PDGF, 
neutralising TGF-β1 and TGF-β2 or adding exogenous TGF-β3 (Ferguson and 
O'Kane 2004). These studies show that it may be the relative proportions of the 
TGF-β isoforms, rather than the absolute amount of any one isoform, which 
determines the wound phenotype (Hantash et al. 2008). The effects of TGF-β on 
wound healing will be reviewed in more detail below. 
Foetal extracellular matrix 
Foetal wound healing is seems to be intrinsic to foetal skin and not due to the 
influence of any unique environmental factors (Lorenz et al. 1992; Longaker et al. 
1994). However, a physiologic solution of cytokines and tissue inhibitors of 
metalloproteinases produced from amnion-derived multipotent progenitor cells 
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improves healing in models of acute and chronic adult wounds (Franz et al. 
2008), showing that the amniotic environment, while not essential, is in all 
probability still beneficial. Foetal fibroblasts appear to be crucial for scarless 
repair. Foetal fibroblasts migrate faster, synthesise more total collagen, and a 
larger proportion of collagen types III and V, than adult fibroblasts (Bullard et al. 
2003). They also begin synthesising collagen immediately post-injury, whereas in 
the adult, collagen synthesis begins a few days later (Hantash et al. 2008). Foetal 
skin naturally contains higher levels of collagen III at 30% to 60% of total. The 
proportion of collagen III progresses toward adult skin levels (10-20%) as 
development continues, as does the ability to heal without scar (Bullard et al. 
2003). The ability to turnover ECM during wound healing may also be an 
important difference in foetal wound healing. Differences in MMP/TIMP ratios 
have been reported which may allow more rapid ECM turnover and lead to 
scarless repair (Bullard et al. 2003). 
 
Table 1.4: Qualitative differences between foetal and adult wound healing 
(From Adzick and Lorenz 1994; Bullard et al. 2003). 
Foetal factors  Adult factors 
Amniotic fluid, sterile environment Dry, contaminated environment 
Rapid cell proliferation Slow cell proliferation 
Rapid closure and epithelialisation Slow closure and epithelialisation 
Less differentiated skin Fully differentiated skin 
More hyaluronic acid and non-sulfated 
GAGs 
Less hyaluronic acid and more sulfated GAGs 
Oxygen tension lesser Oxygen tension greater 
Little inflammation Massive inflammation 
TGF-β3 isoform predominant TGF-β1 isoform predominant 
Fibromodulin is predominant TGF-β 
modulator 
Decorin is predominant TGF-β modulator 
Platelets: less degranulation of active 
cytokines 
Platelets: potent degranulation of active 
cytokines 
Faster and organised matrix deposition Slow and disorganised matrix deposition 
More fibronectin and tenascin; more 
fibroblast migration 
Slower fibroblast migration 
High proportion of collagen type III Low proportion of collagen type III 
No inflammatory effector cell Macrophage is inflammatory effector cell 
Scarless Scar 
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1.4.4 Burn wounds 
Burn wounds are unique among wound types, and are treated as such in the 
literature. Therefore, a brief review of the characteristics which make burn 
wounds unique follows. 
Depth and degree 
Burn injuries can result from thermal, electrical or chemical insult. Superficial 
burns present with pain, redness, and/or blistering and usually heal within 14 
days with minimal scarring (Benson et al. 2006). Healing with excessive scarring 
is a characteristic of deep burn wounds and this can lead to fibrotic disorders 
such as hypertrophic scarring and contracture. Burn wounds are rated for severity 
by degree. First degree burns do not go beyond the basal epidermal layer; 
sunburn is an example of a first degree burn. Second degree or partial thickness 
burns extend past the epidermis but not totally through the dermis. Second 
degree burns can be subdivided into superficial and deep second degree burns. 
The effectiveness of healing of second degree burns is related to the number of 
adnexal structures left intact, which assist in re-epithelialisation, such as hair 
follicles and glands (Greenhalgh 1996). Third degree burns of the skin are the 
most severe as they extend all the way through the dermis. With hair follicles and 
other adnexa destroyed, these wounds cannot heal by epithelialisation and may 
require surgical intervention and/or skin grafting (Greenhalgh 1996). Burn depth 
is the most important factor in determining morbidity and mortality of the patient 
(Heimbach et al. 1992). The depth of injury depends on four factors: temperature 
of contacting agent, duration of contact, thickness of the skin, and the blood 
supply (a more vascular tissue will dissipate heat faster and reduce depth of 
injury) (Greenhalgh 1996).  
Burn wound zonation 
The area of a burn wound has been described in terms of three distinct zones: a 
central zone of necrosis, surrounded by a zone of stasis, with a further 
surrounding zone of hyperaemia (increased blood-flow giving red appearance) 
(Jackson 1953). The tissue in the central necrotic zone is damaged beyond 
recovery, but the tissue in the outer zone will recover fully (Mahajan et al. 2006). 
The zone of stasis results from significant damage to surrounding tissue 
occurring after the removal of the thermal source, with cell death occurring 
through both necrosis and apoptosis (Giles et al. 2008). An area of interest in 
burn wound healing is therefore the zone of stasis where blood flow in the 
capillaries slows down and can eventually stop, leading to a further progression 
 43 
 
of size and depth of injury known as secondary aggravation (Mahajan et al. 
2006). This zone is viable for the first 24 hours following the trauma, but may 
progress to necrosis afterwards (Zor et al. 2005). Whether the zone of stasis‘ 
progression to necrosis can be interrupted or even reversed is the subject of 
much research with the aim to improve healing and reduce scarring in burn 
wounds. 
Contrasting elements of burn wounds with other wound types 
The zone of stasis is the most obvious difference between burn and other wound 
types and has a significant impact on healing with regard to blood flow. Damage 
to blood vessels causes restriction or cessation of blood flow in the immediate 
area of the wound and modifications to blood flow in surrounding areas 
(Shakespeare 2001). Another key difference is the extent and duration of the 
inflammatory phase in burn patients where the wound remains open for 
prolonged periods (Greenhalgh 1996). For a chronically open burn wound, the 
inflammatory phase blends with the proliferative phase where continued 
production of cytokines and growth factors leads to fibroblast proliferation and 
synthesis of ECM, resulting in increased scarring (Greenhalgh 1996). Burn-
injured dermal tissue contains significantly increased amounts of collagen type III 
for a prolonged time and this may be a marker for the extent of fibrosis (Garcia-
Filipe et al. 2006). 
1.4.5 Wound models 
Wound healing studies have been successfully conducted on several in vivo 
animal models including rat, mouse, guinea pig, opossum, rabbit, horse, sheep, 
pig and human. Most wound healing studies aim to contribute to knowledge that 
may one day benefit human wound healing. Therefore selection criteria for 
suitable animal models need to balance the cost, availability and ease of handling 
of animal subjects with the appropriateness of applying such research to human 
wound healing scenarios. The most appropriate model to use in many studies is 
the human model (Lindblad 2008), but the obvious practical and ethical 
considerations often render this option unrealistic. For this reason, animal models 
can make suitable alternatives. The pig is arguably the most suitable animal to 
study as a model for human cutaneous wound healing. Pig skin is anatomically 
and physiologically similar to human skin in several ways including thickness of 
the epidermis, dermal to epidermal thickness ratio, collagen biochemistry, 
number and distribution of blood vessels and other cutaneous structures such as 
hair follicles, and the fact that the skin is well-fixed to the underlying musculature 
 44 
 
unlike smaller loose-skinned mammals such as the mouse (Sullivan et al. 2001). 
However, cost, availability and ease of handling, as well as short gestation and 
short lifespan, dictate that most wound healing studies are conducted on rodents.  
1.4.6 General effects of cytokine and growth factor 
manipulation 
Most wound healing studies aim to manipulate one or more cytokines or growth 
factors (or their receptors) involved in wound healing in order to study their 
effects, or in an attempt to improve wound healing. This can be achieved by 
methods such as transgenic knockout, gene over-expression or inducible 
expression, or by topical application or systemic injection of exogenous growth 
factors.  
 
In most cases the effects of exogenous growth factors on the healing process has 
been beneficial. To date only PDGF-BB has been approved by the United States 
Food and Drug Administration (USFDA), though only for use in diabetic foot ulcer 
(Branski et al. 2006; Riedel et al. 2006). Transgenic animals are used to give an 
insight into the potential usefulness of a particular gene for gene therapy. By 
inserting a desired gene into recipient cells, gene therapy has the potential to 
make improvements in wound healing where exogenous or systemic application 
of growth factors has seen limited success (Eming et al. 2007b; Hirsch et al. 
2007). Table 1.5 outlines the typical results of such trials. 
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Table 1.5: Effect of topically applied growth factors and cytokines 
Growth factor/ 
cytokine applied 
General effect 
PDGF-BB Increased neovascularisation 
Increased re-epithelialisation 
Increased granulation tissue 
Accelerated wound healing 
Enhanced ulcer closure 
TGF-β2 Increased collagen content of granulation tissue. 
TGF-β3 Enhanced wound healing 
Decreased scarring 
FGF-2 Increased neovascularisation 
Increased re-epithelialisation 
Accelerated ulcer closure 
FGF-1 Increased neovascularisation 
Increased matrix deposition 
EGF Increased re-epithelialisation 
Accelerated wound healing 
TGF-α Accelerated healing of chronic wounds 
IL-1β Accelerated wound healing especially in infected open 
wounds 
CSF-2 Increased healing in incisional wounds and chronic ulcers 
CCL-2 (MCP-1)  Accelerated healing of chronic wounds 
CCL-3 (MIP-1α) Accelerated healing of chronic wounds 
IFN-γ Attenuation of fibrosis in keloids 
VEGF-A Accelerated healing of ischemic wounds 
IGF-1 Accelerated wound healing 
(Based on reviews by Pierce and Mustoe 1995; Gharaee-Kermani and Phan 
2001; Werner and Grose 2003) CSF: Colony Stimulating Factor, MCP: Monocyte 
Chemotactic Protein, MIP: Macrophage Inflammatory Protein, CCL: Chemokine 
(C-C motif) Ligand, IFN: Interferon. 
1.4.7 Specific effects of some key factors 
Myostatin 
Structure, processing and signalling 
Myostatin, also known as Growth and Differentiation Factor-8 (GDF-8), is a 
member of the transforming growth factor-beta superfamily. The TGF-β 
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superfamily contains more than 30 structurally-related polypeptide growth factors 
including TGF-βs (1–3), activins (A, B), inhibins (A, B), bone morphogenetic 
proteins (BMPs 1–20), growth differentiation factors including myostatin, nodal, 
leftys (1,2), and Müllerian-inhibiting substance (MIS) (Gordon and Blobe 
2008).The superfamily is characterised by a conserved carboxy-terminal feature 
consisting of seven cysteine residues, six of which form a rigid cystine (the 
oxidised dimer of cysteine) knot, a structure which almost all family members 
share (O'Kane and Ferguson 1997) (see Figure 1.12). Like other family members, 
myostatin is synthesised and secreted as a large inactive pro-peptide with three 
distinct regions: an inactive precursor protein with a signal sequence required for 
processing and secretion, the latency-associated peptide (LAP) domain which 
regulates biological activity of myostatin, and mature myostatin which, as a 
homodimer, binds to the receptor (Patel and Amthor 2005). Myostatin has a 
RSRR (arg ser arg arg) proteolytic processing site in the C-terminal half of the 
protein, which when processed forms the biologically active C-terminal ‗mature‘ 
protein. Mature myostatin contains nine cysteine residues from which the 
characteristic cystine knot structure is formed to allow for homodimerisation (Lee 
2004).  
Signalling 
TGF-β family members exert their effect by binding to type II receptors, which 
recruit and activate by phosphorylation type I receptors via serine/threonine 
kinase activity of the type II receptor (Whitman 1998; Glasgow and Mishra 2008). 
Following this, the type I receptor phosphorylates receptor-activated Smad 
proteins (R-Smads) (Faler et al. 2006), R-Smad then associates with a co-Smad 
(Smad4) facilitating translocation into the nucleus (Abdollah et al. 1997) (see  
Figure 1.14). Smad proteins are responsible for transmitting the signals of TGF-β 
family members from the cell membrane into the nucleus and can be grouped into 
three subfamilies; receptor-regulated Smads (R-Smads), common Smads (co-
Smads), and the inhibitory Smads (I-Smads) (Attisano and Tuen Lee-Hoeflich 
2001). Once in the nucleus, Smad complexes activate specific genes through 
cooperative interactions with other DNA-binding proteins (Padgett et al. 1998; 
Glasgow and Mishra 2008). In the case of myostatin, the mature region binds to 
Activin type II receptor B (ActRIIB) and, to a lesser degree, ActRIIA. After 
phosphorylation of the corresponding type I receptor (ActRI), signal transduction 
continues to the nucleus via Smad proteins.  
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Figure 1.12: Growth factor cystine knot motif 
All of the structures in the growth factor class of cystine knots have I-IV, II-V, III-VI 
disulphide linkages with Cys I-IV passing through the ring created by Cys III-VI 
and Cys II-V linkages (McDonald and Hendrickson 1993; Isaacs 1995; diagram 
adapted from Hearn and Gomme 2000). 
 
Function 
Myostatin has been well-characterised as a negative regulator of muscle 
development (McPherron et al. 1997; Lee and McPherron 1999; Lee 2004). A 
dramatic increase in muscle mass is observed in mice where the myostatin gene 
has been disrupted (McPherron et al. 1997) or in cattle where a naturally-
occurring mutation results in absence of myostatin protein or a non-functional 
myostatin protein product, resulting in the heavily-muscled Belgian Blue and 
Piedmontese cattle breeds respectively (Kambadur et al. 1997; McPherron and 
Lee 1997). A similar effect has been seen in humans by the identification of a 
child possessing a myostatin mutation (Schuelke et al. 2004) and also in whippet 
dogs (Shelton and Engvall 2007). In the heavily-muscled Texel sheep breed, a 
mutation in the 3‘ untranslated region of the myostatin gene creates a target site 
for highly expressed interfering micro RNAs in muscle, causing inhibition of 
translation of myostatin with subsequent muscle hypertrophy (Clop et al. 2006). 
Conversely, clear links have been drawn between over-expression of myostatin 
and a resulting decrease in skeletal muscle mass. Indeed, in various muscle 
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wasting disease states such as cancer cachexia, up-regulation of myostatin is 
observed (Jespersen et al. 2006; McFarlane et al. 2006).  
Effect on wound healing 
Research on the myostatin gene has tended to focus almost exclusively on its 
effect on muscle development and myogenesis, where it modulates skeletal 
muscle satellite cell activation and controls both differentiation and proliferation of 
skeletal muscle both pre- and post-natally (Walsh and Celeste 2005). However, 
recent research is uncovering another role of myostatin, in wound healing. It has 
been shown that myostatin is involved negatively in adult myogenesis and muscle 
regeneration from injury (Kirk et al. 2000). Recent work in this lab has shown that 
myostatin can impair macrophage chemotaxis, retarding their migration to the site 
of injury, but is chemotactic for fibroblasts likely contributing to enhanced collagen 
deposition (Siriett 2007) (see Figure 1.13 for a proposed model of myostatin 
involvement in wound healing). Enhanced regeneration and reduced fibrosis is 
seen in myostatin-null mice (McCroskery et al. 2005) and in mice treated with a 
myostatin inhibitor after injury (Nozaki et al. 2008). Myostatin is shown to be up-
regulated nearly four-fold in gastrocnemius muscle in response to full thickness 
burn injury to body surface, although E-coli endotoxin or induction of 
polymicrobial sepsis did not significantly alter myostatin mRNA levels in the same 
study (Lang et al. 2001). These studies show that myostatin can be targeted to 
improve the healing process across the phases of wound healing. 
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Figure 1.13: A model for the role of myostatin in skeletal muscle healing 
Following injury to the muscle, satellite cells become activated and migrate to the 
wound site. myostatin inhibits satellite cell activation and migration, and also 
macrophage migration (from McCroskery et al. 2005). Mstn: myostatin, SC: stem 
cell, MB: myoblast.
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Therapeutic potential of targeting myostatin 
Due to the potency of myostatin as an inhibitor of regeneration and promotor of 
fibrosis, it follows that inhibiting myostatin in certain situations would be of 
therapeutic benefit. Several proteins have been discovered that bind and prevent 
myostatin from signalling. These include myostatin propeptide, activin receptor, 
metalloproteases, follistatin and the follistatin-related proteins (Follistatin Related 
Gene (FLRG), and Growth and Differentiation Factor-Associated Serum Protein-1 
(GASP-1)), as well as specific anti-myostatin antibodies which have been 
developed (Patel and Amthor 2005).  
TGF-β1 
TGF-β1 is perhaps the most important factor in the wound healing context and is 
worth special consideration. It has been discovered to have some effect on 
almost every aspect of wound healing. This same cytokine can even have 
different effects depending on cell type and state, for example, cell proliferation 
may be stimulated or inhibited by TGF-β depending on whether the cell is a 
fibroblast or a keratinocyte respectively (Massagué and Wotton 2000). Wound 
TGF-β is released from degranulating platelets and is secreted by all major cell 
types contributing to wound repair including lymphocytes, macrophages, 
endothelial cells, epithelial cells and fibroblasts (Liu et al. 2004).  
Structure and processing 
TGF-β has a similar structure and processing program to myostatin. The TGF-β1 
precursor cleaved of its peptide signal is labelled ‗pro-TGF-β‘ (Lawrence 2001). 
An endoprotease recognises an RHRR (arg his arg arg) site in pro-TGF-β and 
cleaves the molecule, but the two parts remain non-covalently associated and are 
known in dimeric form as ‗small latent TGF-β1‘ (Lawrence 2001). Proteolytic 
cleavage of LAP activates TGF-β1 and this can be achieved through acidic 
conditions or by several extracellular proteases (Gordon and Blobe 2008). One 
free cysteine, which is not involved in the knot structure, forms a disulfide bond 
with an identical monomeric chain to further stabilise the mature TGF-β dimer 
(Verrecchia and Mauviel 2002) 
Signalling 
TGF-β binds to and signals through its type II receptor TβRII, which then recruits 
TβRI to initiate intracellular signalling via Smads, as for myostatin. In the case of 
TGF-β, a type III receptor on the cell surface usually known as ‗TβRIII‘ or 
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otherwise known as the membrane-anchored proteoglycan, ‗betaglycan‘, 
provides high-affinity TGF-β presentation to the type II receptor complex (Derynck 
and Zhang 2003; Liu et al. 2004). 
 
 
 
 
 
The question arises of how a relatively simple system can elicit a variety of 
specific responses. Massagué and Wotton (2000) provide the following useful 
summary on the sequence of events. An incoming Smad complex is met in the 
nucleus by a set of partner proteins that are specific to a particular cell type in one 
of a particular set of conditions. These partners govern the DNA sequences to 
which the Smad complex will bind the transcriptional co-activators or co-
repressors it will recruit, the other transcription factors it will cooperate with, and 
the duration of these effects. The combination of Smad partners and regulators 
present in a given cell at the time of TGF-β stimulation accordingly determines 
the response.  
Effects of TGF-β1 signalling in wound healing 
TGF-β1 has manifold effects in all phases of wound healing by directing the 
functions of monocytes/macrophages, endothelial cells, fibroblasts and 
keratinocytes (Faler et al. 2006). Table 1.6 outlines these various effects. 
TGF-β RI 
TGF-β RII 
Activin RI 
Activin RIIB 
TGF-β 
Myostatin 
Smad2/3 
Smad2/3 
Smad2/3 
RI 
Smad4 
Smad2/3 
RI 
Smad4 
Smad6/7 
Decorin 
Myostatin 
Antagonists 
cytoplasm nucleus 
 
Figure 1.14: Simplified signalling pathways of two TGF-β superfamily members. 
 52 
 
 
Table 1.6: Effect of TGF-β1 on major cell types in wound healing 
Cell Type Effect of TGF-β1 
Monocyte/ 
Macrophage 
Production of TGF-β1 
Chemotaxis and migration into the wound site 
Production of protease inhibitors 
Suppress production of proteases 
Promote macrophage maturation 
Fibroblast Chemotaxis 
Production of TGF-β1 
Proliferation 
Production of ECM components 
Production of protease inhibitors 
Suppress production of proteases 
Differentiation into myofibroblast (Rolfe et al. 2007) 
Endothelial cell Stimulates and inhibits proliferation 
Migration for angiogenesis via induction of cell surface integrins in 
a concentration dependent manner 
Tube formation and maturation (concentration dependent) 
Keratinocyte Decreased proliferation in vitro 
Increased migration and maturation in vitro 
Conflicting results in vivo 
(Adapted from reviews by Beanes et al. 2003; and Faler et al. 2006 except where 
indicated otherwise). 
 
TGF-β1 is principally recognised for its role in scar tissue formation. Evidence of 
this is apparent by its multi-faceted effect on ECM-producing fibroblasts. Early 
studies showed the benefit of exogenous TGF-β1 application on the rate of 
healing and wound-bursting strength. Mustoe et al. (1987) showed that a 220% 
increase in bursting strength was achieved by a single application of exogenous 
TGF-β1 on day two, an effect that was dose-dependent. Also, decreased 
expression of TGF-β1 was observed in chronic leg ulcers (Cowin et al. 2001), but 
clinical trials failed to confirm TGF-β1 as a potential therapeutic agent for wound 
healing (Wang et al. 2006). Other studies shed light on why this may have been 
the case. One group was surprised to observe that mice lacking Smad3 (one of 
the intracellular signal transducers of TGF-β) actually showed accelerated wound 
healing characterised by an increased rate of re-epithelialisation, and also 
displayed impaired inflammatory response with reduced infiltration of monocytes 
(Ashcroft et al. 1999; Ashcroft and Roberts 2000). Delayed healing was observed 
in TGF-β1 overexpressing mice with full-thickness punch biopsy wounds, but 
TGF-β1 did not significantly delay re-epithelialisation in the partial-thickness ear 
wound of animals in the same study (Tredget et al. 2005). Another group 
designed a transgenic animal that over-expressed TGF-β1 in the epidermis 
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driven by the keratin-14 promoter. They reported significantly inhibited re-
epithelialisation of partial thickness CO2-laser-inflicted burns and increased 
collagen type I expression and hydroxyproline, a marker of total collagen content 
(Yang et al. 2001). To corroborate these findings, Shah and colleagues (1992; 
1994; 1995) used neutralising antibodies against TGF-β1 and TGF-β2 which 
resulted in incisional wounds healing with reduced inflammatory and angiogenic 
responses and reduced ECM deposition without reduction in tensile strength. 
Scarring was reduced to the extent that neodermis was similar in architecture to 
normal skin. In the 1995 study, they showed that neutralising both TGF-β1 and 
TGF-β2 concurrently gave the best results and that anti-TGF-β1 alone gave only 
marginally reduced scarring. The above findings, together with the involvement of 
TGF-β3 in the foetal wound healing paradigm, confirm the comprehensive 
influence of TGF-β on wound healing. Any pharmacologic improvement in wound 
healing will likely be due to direct or indirect effects on one or more TGF-β 
isoforms. 
Small Leucine-Rich Proteoglycans 
Decorin 
Decorin, named for its decorative appearance on collagen fibrils, is the prototype 
of the small leucine-rich proteoglycan (SLRP) family (Iozzo 1998; Delehedde et 
al. 2002). SLRPs consist of a central domain of leucine-rich repeats with small 
cysteine clusters to either side (Hocking et al. 1998). Decorin-knockout mice have 
fragile skin and abnormal collagen fibril morphology showing that decorin is 
important for collagen fibrillogenesis (Danielson et al. 1997). Decorin binds to the 
fibrillar collagens (types I, II, III, V, and XI) (Beanes et al. 2001) and also TGF-β 
(Burton-Wurster et al. 2003), and is important for wound healing because of its 
ability to regulate ECM assembly and growth factor activity (Beanes et al. 2001). 
While decorin seems to modulate TGF-β, the opposite is also occurs with decorin 
being down-regulated by TGF-β (Iozzo 1998). During the remodelling phase of 
wound healing, hyaluronic acid is replaced by sulphated proteoglycans such as 
decorin, produced by mature scar fibroblasts (Miller and Nanchahal 2005). In the 
presence of decorin, collagen fibrils form more slowly allowing time for optimal 
interaction, resulting in structurally ideal fibre diameters (Reed and Iozzo 2002). A 
specific amount of decorin relative to collagen is probably necessary for optimal 
fibre formation and any deviation from the optimal ratio appears to have a 
negative impact on collagen fibre formation and overall dermal structure (Lochner 
et al. 2007). Decorin also induces the expression of MMP-1 (Huttenlocher et al. 
1996). The MMPs and their associated TIMPs are thought to be critical for wound 
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ECM remodelling, and possibly the scarless wound healing phenotype (Beanes 
et al. 2001). 
Fibromodulin 
Fibromodulin, like decorin, binds to type I and type II collagens (Viola et al. 2007; 
Vélez-delValle et al. 2008) and influences the rate of fibrillogenesis and the 
structure of fibrils (Delehedde et al. 2002) as its name suggests. There seems to 
be no competitive inhibition between fibromodulin and decorin binding to 
collagen, suggesting that these two members of the gene family bind to different 
sites on the collagen fibril (Svensson et al. 1999). Fibromodulin seems to be the 
main modulator of TGF-β in the foetal wound healing context (Bullard et al. 2003). 
 
Other SLRPs not discussed here include biglycan, lumican, epiphycan, 
osteoglycin, chondroadherin, and keratocan. 
Relationships between myostatin, decorin and TGF-β in wound healing 
Zhu et al. (2007) have recently elucidated the relationship between TGF-β1, 
decorin, and myostatin. They discovered that myostatin stimulated fibroblast 
proliferation in vitro and induced its differentiation into myofibroblasts. They also 
found that TGF-β1 stimulated myostatin expression, and conversely, myostatin 
stimulated TGF-β1 secretion in C2C12 myoblasts. Decorin was found to 
neutralise the effects of myostatin in both fibroblasts and myoblasts and decorin 
up-regulated the expression of follistatin, a natural antagonist of myostatin. Their 
subsequent in vivo studies showed improved muscle regeneration with reduced 
fibrosis in myostatin-null mice and concluded that myostatin has fibrogenic 
properties. An earlier study (McCroskery et al. 2005) concurred with these results 
and suggested that myostatin negatively regulates decorin mRNA expression. 
Therefore by removing myostatin, the ensuing up-regulation of decorin 
neutralises TGF-β and the result is decreased scar tissue formation. Zhu et al. 
(2007) discuss that fibroblasts may be a source of myostatin and that in injured 
muscle, myostatin activates fibroblasts by stimulating fibroblast proliferation. 
Myostatin may then attract fibroblasts to an injury site, further inducing them to 
express myostatin in an autocrine fashion. The fibroblasts then differentiate into 
myofibroblasts, thereby accelerating the deposition of the ECM. A current study 
has provided evidence that myostatin directly stimulates muscle fibroblast 
proliferation and expression of ECM proteins in vivo as well as in vitro, and that 
muscle fibroblasts express functional myostatin, which signals through the 
ActRIIB receptor inducing proliferation via the canonical Smad pathway (Li et al. 
2008).  
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1.5 Aims, Objectives, and Hypothesis 
Up untill the present time, research on the function of myostatin has revealed its 
role as a powerful negative regulator of muscle development. Recently, work in 
this lab by McCroskery et al. (2005) and Siriett (2007) has been conducted on 
myostatin‘s role in adult myogenesis in response to muscular injury, and its 
negative regulation thereof . These studies indicate that myostatin has a clear 
role in muscle wound healing, and that removing or antagonising myostatin leads 
to improved healing and reduced scar tissue formation. The present study will 
attempt to apply these findings to wound healing in skin, where the wound 
healing processes and biology are essentially alike, with many of the same 
molecular pathways operating in both. Myostatin is primarily expressed in skeletal 
muscle and it is also found, in mature form, in the circulation (Hosoyama et al. 
2006). Therefore, it is likely that myostatin diffuses into the skin. It has been 
shown that the same receptor (ActRIIB) that binds myostatin in the muscle is also 
present in the skin (Hübner and Werner 1996; Lai and Pittelkow 2004; Bamberger 
et al. 2005), indicating the possibility that myostatin may have a function in skin. 
Consequently, by antagonising myostatin, skin healing could be improved, 
fibrosis avoided, and progression to a pathologic state prevented. 
 
Presently there is no data available on the effect of myostatin on skin and this 
represents a gap in the scientific literature. Therefore, the aim of this project is to 
apply knowledge of myostatin‘s action in a muscle healing model to a skin healing 
model, and by doing so, establish whether antagonising myostatin can lead to 
improved wound healing in skin.  
 
1.5.1 Skin burn injury model 
Burn wounds differ significantly from other types of wound. The most important 
difference is the amount of necrotic tissue remaining, and the viability of the 
surrounding zone of stasis. While the healing of burn wounds follows through the 
same course of events as other wounds, burn wounds often take longer to heal 
and lead to increased accumulation of scar tissue. Therefore, the uniqueness of 
burn wounds necessitates the development of a specific burn wound model. 
 
One of the challenges in establishing a burn injury model is standardisation of the 
burn wound. Another consideration is whether a partial thickness or a full 
thickness injury is required. Some of the early models of burn wound healing in 
the 1970s involved the ignition of ethanol on a standard sized area marked out by 
 56 
 
flame resistant plastic (Neely et al. 1999). Other types of thermal injury have 
included scald injury from 100°C water (Ballard-Croft et al. 2004), hot wax burn 
(Bairy et al. 1997), flame burn (Sakurai et al. 2002), and various metal objects, 
usually brass, heated in boiling water (Papp et al. 2005; Willis et al. 2005; Moller-
Kristensen et al. 2006; Moller-Kristensen et al. 2007). All of these methods were 
not considered suitable in the interests of animal welfare by the Ruakura Animal 
Ethics Committee, because of the extent of injury, and therefore suffering, 
caused. Burns inflicted by CO2 lasers possess the advantage of reduced 
variability by maintaining a consistent depth (Yang et al. 2001; Cohen et al. 2003; 
Bilic et al. 2005). Other considerations include the use of analgesics for pain relief 
and whether these interfere with healing (Dorsett-Martin 2004), and the 
placement of the burn in a position where it cannot be interfered with by the 
animal itself. The model developed in the present study differs from others in that 
it uses a small stainless steel bar, heated in a flame before being applied to the 
skin for five seconds, to cause a severe, though very localised, deep burn injury. 
 
1.5.2 In vivo trial using skin burn injury model 
The major aim of this study is to test the efficacy of antagonising myostatin using 
the burn injury model described above. The methods for achieving this aim 
include: total collagen analysis (as an indicator of scar tissue formation), gene 
expression analysis of collagen type I, collagen type III, TGF-β1, TGF-β3, 
decorin, and fibromodulin (all involved in wound healing and scar formation), and 
histological analysis to ascertain the effects of treatment on granulation tissue 
formation and collagen deposition. 
 
1.5.3 Hypothesis and Objectives 
It is hypothesised that the administration of a myostatin antagonist will have a 
similar effect on skin healing as it has been shown to have on muscle healing. In 
particular, the administration of a myostatin antagonist will result in the 
expression of genes associated with accelerated healing and deposition of 
collagen associated with reduced scarring after burn injury compared with the 
administration of saline as a control. The specific objectives follow from the aims 
of this study mentioned above. Therefore, the specific hypothesis and objectives 
are stated as follows: 
 
 57 
 
Hypothesis: 
Antagonising myostatin following burn injury will result in significant and 
quantifiable improvements in wound healing. 
Objective 1: 
To develop and test a murine skin burn injury model suitable for this and future 
studies of burn wound healing in skin. 
Objective 2:  
To determine the effect of a myostatin antagonist on skin healing after severe 
thermal injury. 
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2 METHODS & MATERIALS 
2.1 Materials 
2.1.1 Hydroxyproline assay reagents 
 
Table 2.1: Hydroxyproline assay reagents 
Reagent Composition Amount Manufacturer 
Standard Hydroxyproline standard 
 
0.1% w/v Sigma-Aldrich 
Acetate Citrate 
Buffer 
 
Sodium Acetate Trihydrate 
Citric Acid 
Sodium Hydroxide 
Acetic Acid 
Adjust to pH 6.5, volume to 100 ml 
 
12 g 
4.6 g 
3.4 g 
1.2 ml 
J.T. Baker 
BDH Chemicals 
Merck 
VWR International 
Chloramin T 
reagent 
Chloramin T 
50% v/v n-propanol 
Dissolve then adjust to final vol of 10 
ml with acetate citrate buffer 
 
0.127 g 
2 ml 
Sigma-Aldrich 
VWR International 
Ehrlich’s reagent p-dimethylaminobenzaldehyde 
2:1 n-propanol : perchloric acid 
Dissolve and adjust to 10 ml  
1.5 g 
8 ml 
Fluka 
VWR International 
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2.1.2 Gene expression analysis reagents 
 
Table 2.2: Gene expression analysis reagents 
Process Reagent/Product Amount Manufacturer 
RNA extraction TRIzol® Reagent 
Chloroform 
Isopropanol 
1 ml/ 
sample 
Invitrogen 
BDH Chemicals 
BioLab 
cDNA synthesis SuperScript-II kit  Invitrogen 
PCR 10x Choral Load PCR Buffer  Qiagen 
 5x Q solution  Qiagen 
 dNTPs  Invitrogen 
 Oligonucleotide Primers  Invitrogen 
 Taq Polymerase  Qiagen 
RT-PCR LightCyclertm Master mix  Roche 
 Taq Polymerase  Roche 
 Capillaries 96/box Roche 
DNA purification Wizard PCR prep  Promega 
DNA Gel 
Electrophoresis 
Agarose  
Low melting point (LMP) Agarose 
 Gene Choice  
Mercury 
 Ethidium bromide  Invitrogen 
 TAE buffer 
40 mM Tris-acetate 
2 mM EDTA (pH 8.0) 
  
J.T. Baker 
Scientific Supplies 
 DNA 1kb+ ladder  Invitrogen 
 DNA loading dye 
15% ficoll 
0.25% bromophenol blue 
0.25% xylene cyanol 
1% SDS 
1 mM EDTA (pH 8.0) 
  
Sigma 
BDH Lab Supplies 
BDH Lab Supplies 
BioRad 
Scientific Supplies 
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RNA Gel 
Electrophoresis 
Agarose 
2x RNA loading dye 
     10% MOPS (10 x) 
     20% deionised formaldehyde 
     50% deionised formamide 
     0.02% bromophenol blue 
     5% glycerol 
     1 mM EDTA (pH 8.0) 
     40 µg/ml ethidium bromide 
 Gene Choice 
 
Sigma 
Sigma 
Sigma 
BDH Lab Supplies 
VWR International 
Scientific Supplies 
Invitrogen 
 10 x MOPS 
     41.8% MOPS 
     50 mM NaOAc 
     10 mM EDTA 
  
Sigma 
J.T. Baker 
Scientific Supplies 
 Formaldehyde  Sigma 
Denaturing 
Polyacrylamide 
Gel Electro-
phoresis 
Acrylamide/Bisacrylamide 
TEMED 
APS 
Urea 
 BioRad 
BioRad 
BioRad 
BDH Chemicals 
 TBE buffer 
     Tris Base (890 mM) 
     Boric acid (890 mM) 
     0.5 M EDTA, pH 8.0 (20 mM) 
 
27g 
13.75g 
10 ml 
 
J.T. Baker 
BDH Chemicals 
Scientific Supplies 
 Loading Dye   
 10 bp ladder  Invitrogen 
Silver Staining BioRad Silver Staining kit  BioRad 
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2.1.3 Histology Reagents 
Table 2.3: Histology reagents 
Process Reagent composition Amount Manufacturer 
Fixatives 10% Buffered Formalin 
     Formalin (40% formaldehyde) 
     Anhydrous disodium phosphate 
     Sodium acid phosphate 
     Distilled water 
 
100 ml 
6.5 g 
4.0 g 
900 ml 
 
BioLab 
VWR International 
VWR International 
 Bouins Fixative 
     Picric acid (saturated) 
     Formalin (40% formaldehyde) 
     Glacial acetic acid 
 
75 ml 
25 ml 
5 ml 
 
BDH Chemicals 
BioLab 
BDH Chemicals 
Stains Celestine Blue 
     5% ammonium ferric sulfate 
     Celestine Blue 
     Glycerol  
 
100 ml 
0.5 g 
14 ml 
 
BDH Chemicals 
BDH Chemicals 
VWR International 
 Gill’s (1974) Hematoxylin 
     Hematoxylin 
     Sodium iodate 
     Aluminium sulfate 
     Ethylene glycol 
     Glacial acetic acid      
     Distilled water 
 
4 g 
0.4 g 
35.2 g 
250 ml 
40 ml 
710 ml 
 
Sigma-Aldrich 
BDH Chemicals 
BDH Chemicals 
Sigma-Aldrich 
BDH Chemicals 
 
 Scott’s tap-water 
     Sodium bicarbonate 
     Magnesium sulfate 
     Distilled water 
 
2 g 
20 g 
1000 ml 
 
BioLab 
BDH Chemicals 
 
 Gomori’s (1950)Trichrome 
     Chromotrope 2R 
     Light green SF or Analine blue 
     Dodecatungstophosphoric acid 
     Glacial acetic acid  
     Distilled water 
 
1.2 g 
0.6 g 
1.6 g 
2 ml 
200 ml 
 
Scientific Ltd, UK 
BDH Chemicals 
Fluka 
BDH Chemicals 
 
 Eosin Yellowish (1%)  Scientific Ltd, UK 
Other reagents 1% Glacial acetic acid  BDH Chemicals 
 1% Acid alcohol 
     70% Ethanol 
     Hydrochloric acid (conc.) 
 
99 ml 
1 ml 
 
VWR International 
VWR International 
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 50%, 70%, 95%, 100%, Ethanol  VWR International 
 Xylene   BioLab 
 Toluene   BioLab 
 DPX mounting solution  VWR International 
 Poly-lysine adhesive  Sigma 
 Paraffin wax  BDH Chemicals 
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2.1.4 Oligonucleotides used for PCR 
End-point PCR primers 
 
Table 2.4: End-point PCR Primers 
Gene GenBank 
Access # 
Forward Primer 5’ – 3’ 
Reverse Primer 5’ - 3’ 
Product 
size (bp) 
Annealing 
Temp (C) 
Cycles 
18S rRNA NR_ 
003278 
AACGTCTGCCCTATCAACT 
AACCTCCGACTTTGCTTCT 
699 59 8 
Collagen Iα1 BC 
050014 
ATGTCGCTATCCAGCTGACC 
AAGGGTGCTGTAGGTGAAGC 
192 59 28 
Collagen Iα2 AK 
075707 
ACAACGTAGAAGGGGTGTCC 
GTAGGTGAACCTGCTGTTGC 
212 58 35 
Collagen IIIα1 AK 
041115 
ATAAGCCCTGATGGTTCTCG 
ATAAGCCCTGATGGTTCTCG 
195 59 28 
Decorin NM_ 
007833 
TTCCAGGGACTGAAGAGTCTCT 
GCACCCTGAGGAGTTTGTTGTT 
268 59 29 
Fibromodulin NM_ 
021355.3 
TCAATCTCCTTCCAACAGGCAG 
AGCCATCCGTTTAGCCTCAGAT 
382 59 31 
GAPDH AK 
146435 
GTGGCAAAGTGGAGATTGTTGCC 
GATGATGACCCGTTTGGCTCC 
289 62 20 
TGF-β1 BC 
013738 
GACTCTCCACCTGCAAGACC 
AGACAGCCACTCAGGCGTAT 
506 58 29 
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Real-Time PCR primers 
 
Table 2.5: Real-Time PCR Primers 
Gene GenBank 
Access # 
Forward Primer 5’ – 3’ 
Reverse Primer 5’ - 3’ 
Product 
size (bp) 
Annealing 
Temp (C) 
Collagen Iα1 BC050014 ATGTCGCTATCCAGCTGACC 
AAGGGTGCTGTAGGTGAAGC 
192 60 
Collagen IIIα1 AK041115 ATAAGCCCTGATGGTTCTCG 
ATAAGCCCTGATGGTTCTCG 
195 61 
Decorin NM_007833 TTCCAGGGACTGAAGAGTCTCT 
GCACCCTGAGGAGTTTGTTGTT 
268 60 
Fibromodulin NM_021355.
3 
GCTGTACGTCCGGTTGTCTC 
GAACTCATTGATCCTGTTGCCC 
175 60 
Histone H3.3A NM_008210 GGCTCGTACAAAGCAGACTGCC 
GCAATTTCTCGCACCAGACG 
225 60 
TGF-β1 BC013738 GCAACAATTCCTGGCGTTACC 
GGCTGATCCCGTTGATTTCC 
198 60 
TGF-β3 AK132519.1 GCGGAGCACAATGAACTGG 
GCTCATCCGGTCGAAGTATCTG 
193 60 
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2.2 Methods 
2.2.1 Burn trial 
Burn injury 
Animal ethics approval was obtained from both the University of Waikato and the 
Ruakura Animal Ethics Committees (Application number 11315, amendment 
number 817) prior to any animal manipulations. On day zero, 104 approximately 
9 month-old, male C57bl mice were inflicted with a burn injury. Briefly, mice were 
anaesthetised, shaved, tagged, weighed, and inflicted with a burn injury on each 
side of the upper back just below the shoulder and parallel to the midline using a 
red-hot metal rod (1.5 mm wide, 7 mm long) which was applied to the skin for 5 
seconds. The skin was lifted between thumb and forefinger and folded over 
forefinger to prevent the heat from damaging structures underlying the skin. 
Tattoos were then applied marking around the area 2-3 mm from the edge of the 
wound. The mice were then placed on a heat pad at 37°C to recover from the 
anaesthetic. 
Injection of antagonist or saline 
Trial mice were age-matched and divided into two study groups where 48 were 
saline-treated and 48 were Mstn-ant4-treated. A couple of extra mice were added 
to each group to compensate for trial mice being withdrawn from the trial because 
of illness or some other unforeseen reason. Mice were injected subcutaneously 
with either saline or recombinant Mstn-ant4 antagonist at a concentration of 6 
µg/g of body weight in a volume of 0.2 ml (29 gauge needle) on days 1, 3, 5, 7, 
10, and 15 after injury. 
Tissue collection 
Six animals from each group were sacrificed on days 2, 4, 7, 14, 21, 28, 35, and 
46. Burn wounds were excised along with matching sized areas of uninjured skin 
from the shaved lower back and either snap-frozen in liquid nitrogen for RNA and 
collagen analysis or fixed in 10% phosphate-buffered formalin for histology. 
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Figure 2.1: Burn injury 
A: Method of causing burn injury. B: Position of each burn injury after application 
of burn causing agent (between arrowheads). 
A. 
B. 
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2.2.2 Antagonist preparation 
Myostatin antagonist preparation was performed by Carole Berry (AgResearch 
Ltd). Various myostatin antagonists have been developed and tested. They are 
essentially a truncated form of mature myostatin. The myostatin antagonist used 
in the present study was named ‗Mstn-ant4'. This carboxy-terminal truncation 
spanning amino acid 266 – 310 was produced using an E. coli expression system. 
Amplified cDNA was purified and subsequently inserted into the cloning vector 
pET 16-B (Novagen) as described in Sharma et al. (1999).  
 
 
Figure 2.2: Myostatin antagonists created at AgResearch Ltd. 
2.2.3 Hydroxyproline assay 
Total collagen was measured by hydroxyproline assay. It was used to assess a 
difference in treatment with respect to collagen deposition. The amino acid 
proline occurs at a relatively constant frequency in the synthesis of collagen 
molecules. Hydroxyproline results from a post-translational modification of proline 
and this can be oxidised to form a chromophore whose absorbance can be read 
at 550 nm. In this study, a method for the determination of hydroxyproline was 
established with modifications from published methods by Stegemann and 
Stalder (1967), Edwards and O'Brien (1980), and Reddy and Enwemeka (1996).  
Sample hydrolysis 
Excised skin samples were retrieved from -80°C, weighed and dried overnight at 
55-60°C in an oven. Dried tissue was weighed to determine water content of skin. 
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Tissue was then cut into small pieces, re-weighed and placed in a 15ml neoprene 
tube with 6 ml of 6 N HCl. The tube was punched through a tinfoil-covered 1 L 
beaker of water to hold it in place, which was then placed inside a pressure 
cooker set at 120°C for 1 h. 1 ml of hydrolysed skin in acid was pipetted into a 1.7 
ml eppendorf tube and centrifuged to remove any remaining ash. 
Assay 
A standard curve was included for every assay run which included varying 
concentrations of standard hydroxyproline (Sigma-Aldrich). 10 µl of each sample 
was added to 40 µl of Milli-Q water in a 1.7 ml eppendorf tube, in triplicate. 450 µl 
of freshly made Chloramin T reagent was then added, briefly mixed and 
incubated in a water bath at 27°C for 30 min. Tubes were then placed on ice to 
stop the reaction. 500 µl of freshly made Ehrlich‘s reagent was then added, mixed 
and incubated for a further 20 min at 60°C after which tubes were placed on ice to 
stop the reaction. 100 µl aliquots were then placed in duplicate in a 96 well plate 
which was then read at 550 nm on a Versamax plate reader using SOFTmax pro 
software (Molecular Devices). Hydroxyproline quantities were calculated from the 
standard curve and then converted to percentage of collagen in sample using a 
7.46 conversion factor (Neuman and Logan 1950). 
2.2.4 RNA extraction 
Total RNA was extracted from skin using TRIzol® Reagent (Invitrogen), 
according to the supplied instructions. 1 ml of TRIzol® Reagent was added to 
frozen skin which was homogenised using a power homogeniser (Global 
Science) for approximately 1 min. Following homogenisation, insoluble material 
from the homogenate was removed by centrifugation at 12,000 × g for 10 min at 
4°C. The supernatant was transferred to a new tube. The resulting pellet 
containing extracellular membranes, polysaccharides, and high molecular weight 
DNA, was retained for possible later protein extraction.  
 
Phase Separation: Homogenised samples were incubated for 5 min at room 
temperature to permit the complete dissociation of nucleoprotein complexes. 
Then 0.2 ml of chloroform was added and tubes shaken vigorously by hand for 15 
s and left to incubate at room temp for 2 to 3 min. Samples were centrifuged at 
12,000 × g for 15 min at 4°C. Following centrifugation, the mixture separated into 
a lower red, phenol-chloroform phase, an interphase, and a colourless upper 
aqueous phase containing the RNA.  
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RNA Precipitation: The aqueous phase was transferred to a fresh tube, and the 
organic phase was added to the pellet of insoluble material removed after 
homogenisation and stored at -80°C for later protein analysis. RNA from the 
aqueous phase was precipitated by mixing with 0.5 ml of isopropanol. Samples 
were either incubated at room temperature for 10 min or at 4 or -20°C for 1 – 2 h. 
Samples were then centrifuged at 12,000 × g for 10 min at 4°C. The RNA 
precipitate formed a gel-like pellet on the side and bottom of the tube.  
 
RNA Wash: The supernatant was removed and discarded. The RNA pellet was 
washed once with 1 ml of 75% ethanol mixed by vortexing and then centrifuged at 
7,500 × g for 5 min at 4°C.  
 
Redissolving the RNA: Ethanol was removed and the RNA pellet briefly dried 
then resuspended in 20 µl of diethyl pyrocarbonate (DEPC)-treated water by 
incubating for 10 min at 55 to 60°C.  
 
RNA quantitation: RNA concentration and purity was determined by measuring 
the absorbance at 260 nm and 280 nm. For the purpose of quantitation, it was 
assumed that an A260 of 1.0 is roughly equivalent to 40 µg/ml of ssRNA. The 
A260/A280 ratio is used to assess RNA purity, where a ratio of 1.8-2.1 indicates 
highly purified RNA. Absorbance measurements were made on a Nanodrop ND 
1000 spectrophotometer using supplied software (NanoDrop Technologies Inc) 
RNA was stored at -80°C 
2.2.5 RNA electrophoresis 
RNA electrophoresis was carried out on several samples to check for 
degradation. A 1.2% solution of agarose was made by boiling 0.6 g of agarose in 
36 ml of water for 2 min. To the gel solution cooled to 65°C was added 5 ml 10 x 
MOPS and 9 ml formaldehyde. The gel was poured into a specific RNA 
electrophoresis gel box and, after setting, was immersed in 1 x MOPS running 
buffer. 1 µg of total RNA was incubated with an equal volume of 2 x RNA dye 
(containing ethidium bromide) at 65°C for 5 min, loaded onto the gel, and run at 
60 mA until the dye front had crossed half-way. Separated RNA was then 
visualised by photographing under UV light using a BioRad Gel-doc 2000 and 
Quantity One 4.4 software (BioRad). 
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2.2.6 Reverse Transcription of RNA to generate cDNA 
cDNA was generated from RNA using First-Strand cDNA SuperScript-II Reverse 
Transcriptase System (Invitrogen). RNA samples were diluted to 0.2 µg/µl. After 
quantitation, an appropriate amount of suspended RNA was added to a 0.6 ml 
eppendorf tube and made up to 7 µl with water such that the tube contained 1 µg 
of total RNA. To this was added: 1µl of 10 mM dNTP mix, 1µl of 0.5 µg/µl 
Oligo(dT), and 1 µl of 0.2 µM gene-specific primer for 18S rRNA gene. This 
mixture was then incubated at 65°C for 5 min to denature the RNA then placed on 
ice for at least 1 min. To each tube was added in the following order: 2 µl 10x RT 
buffer, 4 µl 25 mM MgCl2, 2 µl 0.1 M DTT, 1 µl RNaseOUT
tm. The mixture was 
gently mixed and collected by brief centrifugation on a bench-top centrifuge and 
incubated at 42°C for 2 min. To each tube was added 1 µl SuperScript-II RT, 
mixed briefly and collected by brief centrifugation. Tubes were then incubated for 
50 min at 42°C. Incubation at 70°C for 15 min terminated the reaction, and then 
samples were chilled on ice. Remaining RNA template was then degraded with 1 
µl RNAse H for 20 min at 37°C. cDNA was stored at -20°C. 
2.2.7 Polymerase Chain Reaction (PCR) 
Amplification of target cDNA for PCR standardisation and semi-quantitative PCR 
was carrier out using a Programmable Thermal Cycler 100 (PTC-100, BioRad). 
Each 50 µl reaction mixture included: 40.75 µl Milli-Q water, 5 µl 10x Choral Load 
PCR Buffer (Qiagen) which includes MgCl2 (1.5 mM final concentration), 1 µl 10 
mM dNTPs, 1 µl 10 µM forward primer,1 µl 10 µM reverse primer, 0.25 µl Taq 
DNA Polymerase (Qiagen), and 1 µl of cDNA (or water for control sample). In the 
case of 18S rRNA PCR, 10 µl 5x Q Solution (Qiagen) was substituted for 10 µl of 
water. PCR products were electrophoresed for visualisation on a gel as described 
in 2.2.9. 
2.2.8 Primer design and PCR standardisation 
Primers were designed using a combination of PerlPrimer 1.1.16 (Marshall 2004) 
and where possible spanned exons to ensure only mRNA was amplified. Both 
PerlPrimer and Oligocalc (Kibbe 2007) were used to assess chosen primers for 
melting temperature, secondary structures, and self-complimentarity. A BLAST 
search of the NCBI database was conducted to ensure primers were unique to 
the target locus. All oligonucleotides were 19-22 nucleotides long. Cycling 
conditions were determined by trial-and-error beginning with predicted melting 
temperatures from Oligocalc. PCR products were electrophoresed and visualised 
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to determine if a single clear band was present. If visualised gel was not 
satisfactory, annealing temperature was increased by 1°C each time until 
satisfactory results were obtained. 
2.2.9 DNA electrophoresis 
A 1% solution of agarose was made by boiling 0.5 g of agarose for 2 min in 50 ml 
1 x TAE. The gel was cooled to 65°C and cast by pouring into an appropriate gel 
box. 1 µl of ethidium bromide was mixed into the gel and allowed to set. The gel 
was covered with 1 x TAE running buffer. PCR reactions that used Choral Load 
buffer did not require mixing with DNA loading dye. 10 µl of PCR product was 
loaded into each well with one well reserved for a ‗1 kb plus‘ molecular weight 
marker (Invitrogen). Electrophoresis was carried out at 80 V for approximately 1 
h. DNA was then visualised by photographing using a BioRad Gel-doc 2000 and 
Quantity One 4.4 software (BioRad). 
2.2.10 Real-Time Polymerase Chain Reaction (RT-PCR) 
RT-PCR was performed using a Roche LightCyclertm. Reaction capillaries were 
placed into position in a lead block to maintain cool conditions. A master mix for n 
reactions was created which included n x 4.5 µl Milli-Q water, 0.5 µl of 10 µM 
forward primer, 0.5 µl of 10 µM reverse primer, and 2 µl LightCyclertm master mix 
(Roche) which includes 14 µl Taq polymerase (Roche). 7.5 µl of this mixture was 
added to each capillary. 3 µl of 1:10 diluted cDNA template was added to the 
master mix in each capillary by pipetting up and down. Capillaries were loaded 
into the LightCyclertm Carousel. The reaction mixtures were collected at the 
bottom of each capillary using the supplied Roche centrifuge with preset 
parameters. The carousel was then loaded into the LightCyclertm thermal cycler. 
The cycler was set to run for 45 cycles then perform a melt curve. For each gene 
analysed, a standard curve was constructed first by creating a series of dilutions 
of a sample then running a standard RT-PCR on the LightCyclertm. Cycle 
thresholds for each sample were calculated using the standard curve for each 
gene. These were used to calculate concentrations relative to a sample used for 
calibration which was designated a concentration of 1 (or 0.1 for a 1:10 
dilution).These concentrations were then used to calculate gene expression 
relative to the house-keeping gene; in the case of all RT-PCR reactions this was 
Histone H3.3A. Amplified products were run on a 1% agarose gel to check for 
correct sizing. 
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2.2.11 DNA purification 
Occasionally, for genes expressed at a low level, a series of sample dilutions did 
not result in enough points to create a standard curve. In such cases a band from 
the electrophoresed amplified gene product was excised and purified and then 
RT-PCR repeated with a larger amount of DNA. A Wizard PCR prep (Promega) 
system was used to purify electrophoresed DNA. PCR products were separated 
on a low melt gel using low melting point (LMP) agarose (Invitrogen). The DNA 
band of interest was visualised under UV light and excised using a razor blade 
before being placed into a 1.7 ml eppendorf tube. The tube was incubated at 65-
70°C until the gel melted. 1 ml of purification resin was added and mixed gently 
for 20 s. The resin/DNA slurry was then passed through a Wizard mini-column 
using a syringe. 2 ml of 80% isopropanol was then washed through. The syringe 
was removed and the mini-column was centrifuged at 10,000 x g for 2 min. The 
mini-column was then transferred to a new tube and DNA was eluted from the 
column by adding 50 µl Milli-Q water, incubating for 1 min and centrifuging at 
10,000 x g for 20 s. The purified DNA was quantitated on the NanoDrop 1000 and 
diluted appropriately for RT-PCR standard curve construction after calculating 
copy number. 
2.2.12 Copy number calculation 
It was necessary to calculate template copy number so an appropriate dilution 
could be made to calculate a standard curve for a gene using RT-PCR. After 
quantitation this formula was used to calculate copy number: 
 
pmol dsDNA = (µg DNA x 1515)/Nbp where Nbp is the no. of base pairs 
 
This formula could be used since the DNA solution contained an amplified PCR 
product of known length. This method ensured that for the lowest concentration of 
diluted sample there was at least more than one template copy in the reaction 
mixture. 
2.2.13 Denaturing Polyacrylamide Gel Electrophoresis 
(PAGE) 
Denaturing PAGE was used to assess for degradation of oligonucleotide primers. 
A method was established by modification of a published protocol (Ellington and 
Pollard 1998). 12 ml of 20% acrylamide (BioRad) was made up for a 10 cm x 10 
cm x 1.5 mm gel. 8 µl of tetramethylethylenediamine (TEMED, BioRad) and 60 µl 
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ammonium persulfate (APS, BioRad) was added before pouring. Running buffer 
was TBE. Wells were washed by squirting TBE with a Pasteur pipette and 5-50 
ng of ssDNA was loaded per well with loading dye. A 10 bp ladder was loaded in 
lane 1. 
2.2.14 Silver staining of polyacrylamide gels 
Silver Stain Plus from BioRad was used to visualise polyacrylamide gels. After 
electrophoresis, gels were placed in fixative enhancer solution for 20 min with 
gentle agitation containing 50% methanol, 10% acetic acid, 10% Fixative 
Enhancer Concentrate, and 30% Milli-Q Water. Gels were then washed in two 
changes of water with gentle agitation for 10 min each. A staining solution 
containing 35% Milli-Q water, 10% Silver Complex Solution, 10% Reduction 
Moderator Solution, 10% Image Development Reagent and 50% Development 
Accelerator Solution was used to develop staining until the desired level of 
staining was achieved. Gels were placed in 5% acetic acid for 15 min to stop the 
reaction. 
2.2.15 Histology 
Fixation 
Individual skin samples were placed inside histology cassettes and fixed 
immediately after excision. The fixative used was 10% buffered formalin for at 
least 48 h duration to ensure proper penetration. After this time samples were 
transferred to, and stored in, 70% ethanol until processing. 
Processing 
Samples were processed in a Leica Tissue processor (Global Science) overnight, 
which involved dehydration and paraffin wax infusion. The following day, skin 
samples were mounted in wax blocks in preparation for sectioning. Sections were 
cut at a thickness of 7-8 µm, placed in a 60°C water bath and mounted on glass 
slides pre-treated with poly-lysine adhesive solution and dried at 37°C overnight. 
Hematoxylin & Eosin (H & E) Staining 
Sections were deparaffinised and rehydrated by immersion in 100% xylene (2 x 5 
min), then 100% ethanol (2 min), then 95% ethanol (2 min), then 70% ethanol (2 
min), then 50% ethanol (2 min). Slides were then washed briefly in distilled water. 
Sections were then stained with Gill‘s Hematoxylin (5 min). Slides were rinsed 
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with tap-water until clear. Sections were blued with Scott‘s tap-water (2 min), and 
then rinsed with tap-water (2 min). Sections were stained with 1% Eosin Y (2 
min), rinsed in tap-water until clear (plus 2 min). Sections were dehydrated 
through 50% ethanol (3 dips), then 70% ethanol (3 dips), then 95% ethanol (2 
min), then 100% ethanol (2 min x 2). Slides were cleared in xylene (5 min x 2). 
Once slides had dried, DPX mounting solution was applied before placing on a 
cover-slip and allowing to dry overnight. 
Trichrome Staining 
A method for trichrome staining was adapted from Gomori (1950). Slides were 
de-waxed and rehydrated as for H & E staining and re-fixed in Bouin‘s fixative at 
room temperature overnight or for 1 h at 60°C. Slides were removed from Bouin‘s 
fixative and washed in running water until the yellow colour disappeared. Slides 
were rinsed in distilled water and stained in Celestine Blue (10 min), rinsed in 
distilled water and then stained with Gill‘s Hematoxylin (3 min). Slides were then 
washed in running water (2 min), differentiated in 1% acid alcohol to remove over-
staining (2-3-dips), rinsed thoroughly in water, and then blued in Scott‘s tap-water 
(2 min), before being rinsed again in distilled water. Slides were then stained in 
Gomori‘s trichrome stain for 15 min, after which they were checked for staining 
progress and stained for a further 5 min if necessary. Slides were then rinsed 
briefly and differentiate in 1% acetic acid (glacial) for 2 min before dehydrating, 
clearing and mounting as for H & E staining. 
Microscopy 
Stained sections were viewed on a Leica AF6000 microscope (Leica 
Microsystems Ltd.) with an attached Leica DFC300FX digital camera. Images 
were captured using the Leica Application Suite Version 2.5.0.R1 software (Leica 
Microsystems Ltd.). Sections were analysed using Image-Pro Plus (Media 
Cybernetics) software and measured for wound area, wound depth, wound 
length, and epidermal thickness. Wound contraction was assessed histologically 
in a similar manner to Fukai et al. (2005). The shortest distance between the 
dermal wound margins, which corresponded to the span of the granulation tissue 
was measured (van Rossum et al. 2007), and presented in most cases with an 
hour-glass type morphology. Granulation tissue thickness was assessed by 
measuring the vertical span of the granulation tissue in three regions of the 
wound which were then averaged to determine approximate thickness after 
Joseph et al. (1997). 
 75 
 
 
 
 
 
 
Figure 2.3: Histological analysis using Image-Pro Plus 
A: Granulation tissue width was determined by bisecting the wound area by 
drawing a line perpendicular to the general plane of the epidermis, then 
measuring the distance to the nearest wound edge perpendicular to that line. B: 
Sometimes a ‗Sorbel‘ filter was useful for more clearly distinguishing the wound 
edge. These measurements were used to indicate the degree of wound 
contraction. 
A. 
B. 
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2.2.16 Statistics 
Data were analysed using analysis of variance (ANOVA) to compare the 
treatments and the burn effect; the ANOVA also accounted for the repeat 
observations (burn & control) being on the same animal. GenStat software was 
used for the ANOVA analysis.  
 
For the gene expression analysis, the data were transformed to approximate 
normality with constant variance by using the loge (natural log) transformation, 
and error was computed as the standard error of the difference between means 
(SED) which was pooled across all days. Tests of significance (t-tests) were 
derived after performing ANOVA on rank transformed data with pooled standard 
deviation. Statistically significant differences were also detected using Student‘s 
t-tests of individual time points. 
 
For all data, a probability (p) value of less than or equal to 0.05 was considered 
significant, where (*) represents a p-value of less than or equal to 0.05, (**) 
represents a p-value of less than or equal to 0.01, and (***) represents a p-value 
of less than or equal to 0.001. 
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3 RESULTS 
Myostatin is well established as a powerful negative regulator of embryonic and 
post-natal muscle development (Kambadur et al. 1997; McPherron et al. 1997). 
Myostatin‘s inhibitory role in myogenic wound healing has also recently been 
described (McCroskery et al. 2005; Siriett 2007; Nozaki et al. 2008). Various 
methods of inhibition or antagonism targeting myostatin have been investigated 
as a means of improving muscle development (Tsuchida 2004; Bishop et al. 
2005; Patel and Amthor 2005) and healing (Nozaki et al. 2008). Myostatin 
expression has not been detected in skin, but its receptor ActRIIB is present in 
both keratinocytes and dermal fibroblasts (Hübner and Werner 1996). Therefore, 
it remains a possibility that myostatin might have some effect on wound healing in 
skin, and that antagonising myostatin may result in quantifiable improvements in 
wound healing. 
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3.1 Effect of myostatin antagonist on weight 
recovery after injury 
Since blocking myostatin has been shown to alleviate muscle wasting conditions 
such as sarcopenia (Siriett et al. 2007), cachexia (Liu et al. 2008) and muscular 
dystrophy (Bogdanovich et al. 2002), it may also help to regain losses in normal 
body weight which occur following traumatic injury (Jeschke et al. 2008). In the 
present study, body weights of all mice were measured on day zero of the burn 
trial. Body weights were re-measured at each collection time point when 6 saline-
treated mice and 6 Mstn-ant4-treated mice were sacrificed for tissue collection. 
The following formula was used to calculate the percent change in body weight 
where PWn is the percentage of day 0 body weight on day n, Wi is the initial body 
weight on day 0, and Wn is the body weight on day n. 
 
 
 
 
The burn trauma (and likely anaesthetic effects also) did appear to cause a 
significant (p=0.04) loss of body weight of up to 10% of initial weight during the 
first four days after injury. Figure 3.1 shows that the Mstn-ant4-treated group had 
recovered their lost body weight by day 21, whereas the body weight of saline-
treated mice was significantly lower (p=0.02), and did not fully recover until day 
28. 
 
 
PWn  =   x 100 
Wi — Wn 
Wi 
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Figure 3.1: Body weight data for duration of trial 
Body weight data is expressed as a percentage of body weight at day 0. Error 
bars represent standard error of the mean (SEM). For each point, n=6 (data for 
day 2 was not collected). 
 
3.2 Effect of myostatin antagonist on total 
collagen 
Collagen was estimated using the hydroxyproline assay. In the present study, 
collagen was expressed as a ratio of the amount of collagen in control skin 
compared to burned skin for each treatment. There did not appear to be 
significant differences between treatments for the amount of collagen in skin 
samples except at day 28 (p=0.007) (Figure 3.2 B). This increase in ratio seen on 
day 28 was due to similar values obtained from burn and control samples for 
Mstn-ant4 (Figure 3.2 A), giving a ratio of close to 1:1. This would seem to 
indicate that the wound had fully healed. However, this is unlikely to be the case 
as subsequent time points re-establish the differences between burn and control 
samples seen at earlier time points. There is an unexpected significant difference 
in hydroxyproline in control skin at day 21. This could be a response to withdrawal 
of treatment on day 15, leading to an increase in collagen levels in Mstn-ant4-
treated mice. 
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Figure 3.2: Hydroxyproline content and percentage of collagen as a ratio of 
burned to uninjured skin 
A: Actual hydroxyproline measurements for each treatment/effect. For each time 
point, n=6. Error bars represent SEM. B: Hydroxyproline values were converted 
to percentage of collagen. These values were then expressed as a ratio of burned 
skin to uninjured skin and averaged to compare the different treatments. Errors 
are expressed as SEM. Each time point represents the mean of 6 ratios, except 
Mstn-ant4-treated samples of day 7 where n=5 due to loss of sample. 
** 
** 
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3.3 Effect of myostatin antagonist on skin 
hydration 
Well hydrated skin is an indication of its healthy status. Increased hydration of 
keratinocytes positively influences their cytokine profiles and rate of re-
epithelialisation (Dumas et al. 2007; Tandara et al. 2007). Water content of 
excised skin samples was able to be compared between treatments by 
dehydrating the samples and measuring the weight change. For uninjured skin 
the data showed that water content was significantly higher at day 7 (p=0.01), 
remained higher at day 14 (p=0.1), and was again significantly higher at day 21 
(p=0.02) for Mstn-ant4-treated skin as compared to saline-treated skin. A similar 
trend was seen in burned skin samples, but was not significant (Figure 3.3). 
Water content is calculated as the difference between wet and dry weights of skin 
samples and expressed as a percentage of wet weight. 
 
Another observation is that skin hydration decreased significantly between days 2 
and 4 for both saline-treated burned and uninjured skin. The same effect was not 
observed in Mstn-ant4-treated burned or uninjured skin. This indicates that Mstn-
ant4 treatment can also prevent dehydration in surrounding tissue as a result of 
burn injury. 
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Figure 3.3: Skin hydration 
A:  Water content of Mstn-ant4-treated burned skin compared with saline-treated 
burned skin. B: Water content of Mstn-ant4-treated uninjured skin compared with 
saline-treated uninjured skin. Error bars for both plots represent SEM. 
 
** 
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3.4 Gene expression analysis 
In accordance with the main aim of this thesis, gene expression analysis was 
conducted for changes in the expression of genes considered to be indicative of 
improved wound healing in skin. The genes chosen for expression analysis were: 
collagen types I and III as indicators of scar tissue formation; TGF-β1 as an 
indicator of fibrosis; decorin which binds and inhibits TGF-β1; TGF-β3 as 
implicated in scarless foetal wound healing; and fibromodulin as also implicated 
in foetal scarless wound healing. The house-keeping gene for all RT-PCR 
samples was Histone H3.3A. Semi-quantitative PCR was also performed to 
analyse expression for some genes but proved to be inferior in sensitivity to RT-
PCR and therefore results are not included. To make efficient use of time and 
resources, the most important time period to study the effect of administering 
Mstn-ant4 on gene expression by RT-PCR was determined to be days 4 to 21. No 
significant changes in gene expression were observed after day 21.  
 
Mouse number 37 proved to be a consistent outlier according to Grubbs‘ test for 
outliers (Grubbs 1969) in many gene expression datasets, even when 
transformed. After careful consideration, it was removed from all gene expression 
analyses. Mouse 37 was a saline treated animal from day 7; expression values 
from both burn and uninjured control skin for this animal were therefore not 
included in the analysis. 
 
Tests of significance (t-tests) were calculated after ANOVA was performed, and 
at individual time points on loge transformed data. For consistency, only ANOVA 
derived t-tests are included with figures, and where individual time point (ITP) t-
tests are reported in the text, this is explicitly stated. Where fold differences are 
reported, these have been calculated after back-transforming mean log values. 
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3.4.1 Collagen expression 
Levels of collagen gene expression are indicative of the amount of ECM and 
hence scar tissue being produced by fibroblasts. Depending on degree, a 
decrease in collagen expression may be related to a decrease in scarring or at 
least a decreased risk of fibrosis.  
 
In this study, collagen type I expression rose sharply during the first week, did not 
change significantly during the second week, and subsequently fell to around day 
4 levels by the end of the third week for both treatment groups (Figure 3.4 A). 
These observations are consistent with other studies (Scharffetter et al. 1989). 
Collagen type III levels followed a similar pattern (Figure 3.4 B). There were no 
significant differences in collagen expression of any type on either day between 
saline-treated and Mstn-ant4-treated burn-injured mice. However, a trend toward 
a higher ratio of collagen I to collagen III (COL1:COL3) for saline-treated burn 
wounds developed from day 7, and by day 21, this difference was significant 
(p=0.038, ANOVA) (Figure 3.5). An ITP t-test performed on day 7 values also 
demonstrated a significance (p=0.04) between treatments with a higher ratio seen 
in saline treatment (not shown on figure). The implication of this result will be 
discussed in chapter four. Collagen expression levels were only assessed in 
samples of burned skin. 
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Figure 3.4: Collagen Type I (A) and Collagen type III (B) expression 
A: Collagen type I expression is displayed as loge concentration values relative to 
house-keeping gene Histone H3.3A. B: Collagen type III expression is displayed 
as loge concentration values relative to house-keeping gene Histone H3.3A. Error 
bar for both plots represents pooled standard error of the difference between 
means (SED). For each point, n=6 except SAL day 7 where n=5. 
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Figure 3.5: Collagen I relative to Collagen III expression 
Collagen type I expression as a ratio to collagen III. Loge values are used for ratio 
calculation. Error bar represents pooled standard error of the difference between 
means (SED). For all points, n=6 except SAL day 7 where n=5. 
 
3.4.2 TGF-β1 expression 
TGF-β1 was analysed because of the known correlation between its up-
regulation and fibrosis. Typically, expression levels peak at around day 8 (Wang 
et al. 1998), depending on depth and degree of injury.  
 
In this study, TGF-β1 expression peaked at day 7 in burned skin. During the 
following two weeks TGF-β1 levels declined gradually (Figure 3.6). Both saline-
treated and Mstn-ant4-treated burns showed remarkable similarity in these 
trends. The gradual decline in TGF-β1 from day 7 was also true for control skin of 
both treatments. However, on day 4 there was a marked difference in TGF-β1 
expression between treatments (p<0.001, ANOVA) where TGF-β1 in Mstn-ant4-
treated control skin was up-regulated by 4.1-fold (Figure 3.6 B). This result 
suggests that the myostatin antagonist is having an effect on TGF-β1 expression 
in uninjured skin, even though the effect is not seen in burned skin. 
* 
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Figure 3.6: TGF-β1 expression 
A: TGF-β1 expression in burned skin for each treatment displayed as loge 
concentration values relative to house-keeping gene Histone H3.3A B: TGF-β1 
expression in control skin for each treatment displayed as loge concentration 
values relative to house-keeping gene Histone H3.3A. Error bar for both plots 
represents pooled standard error of the difference between means (SED). For all 
points, n=6 except SAL day 7 where n=5. 
*** 
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3.4.3 Decorin expression 
Decorin was analysed because of its ability to bind and sequester TGF-β1. 
Decorin is also an important organiser of collagen, which is essential during 
wound healing. Decorin expression changed little during the first week, but there 
was a gradual though significant decline between day 7 and day 21 in burned 
skin of both treatment groups (Figure 3.7). There was no significant difference 
between treatments on any day for burned skin, although on day 7 an ITP t-test 
gave a p-value of 0.056 bordering on significance. In uninjured skin decorin 
expression levels increased sharply during the first week up to day 7 for both 
treatment groups. Mstn-ant4-treated skin exhibited significantly higher levels of 
decorin on day 7 (2.1-fold, p=0.02, ANOVA), before declining to base levels by 
day 21. An ITP t-test gave a p-value of 0.007 for Mstn-ant4 treatment on day 7 
(not shown on figure). 
 
3.4.4 TGF-β3 expression 
Up-regulation of TGF-β3 is associated with scarless healing in early foetal 
mammals. Paradoxically, its effect markedly contrasts with that of its closest 
relative, TGF-β1, in wound healing. However, in the present study, its expression 
profile was similar to that of TGF-β1. For burn-injured skin, regardless of 
treatment, levels do not significantly change up until day 14, after which they drop 
significantly (Figure 3.8 A). For uninjured skin, Mstn-ant4-treatment showed a 
similar pattern of expression as it did for burn-injured skin. Saline-treated 
uninjured skin however showed significantly less TGF-β3 expression at day 4, 
before showing a similar pattern as Mstn-ant4 treated skin for the remaining days. 
In this case, Mstn-ant4 treatment resulted in a 6.1-fold higher TGF-β3 expression 
level than saline-treated control skin (p<0.001, ANOVA) was seen on day 4. By 
day 7 the difference had decreased to 2-fold due to an increase in TGF-β3 
expression in saline-treated skin, however this difference was only significant by 
ITP t-test (p=0.01, not shown on figure). 
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Figure 3.7: Decorin expression 
A: Decorin (Dcn) expression in burned skin for each treatment displayed as loge 
concentration values relative to house-keeping gene Histone H3.3A. B: Decorin 
expression in control skin for each treatment displayed as loge concentration 
values relative to house-keeping gene Histone H3.3A. Error bar for both plots 
represents pooled standard error of the difference between means (SED). For all 
points, n=6 except SAL day 7 where n=5. 
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Figure 3.8: TGF-β3 expression 
A: TGF-β3 expression in burned skin for each treatment displayed as log 
concentration values relative to house-keeping gene Histone H3.3A. B: TGF-β3 
expression in control skin for each treatment displayed as loge concentration 
values relative to house-keeping gene Histone H3.3A. Error bar for both plots 
represents pooled standard error of the difference between means (SED). For all 
points, n=6 except SAL day 7 where n=5. 
 
*** 
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3.4.5 Fibromodulin expression 
Fibromodulin is up-regulated strongly in foetal scarless wound healing studies 
and as a modulator of TGF-β, is considered to be involved in the anti-scarring 
phenotype of foetal wounds. It also plays a similar role to decorin in the 
organisation of collagen fibres. For fibromodulin expression levels burned skin in 
the present study, there appeared to be an early difference, where Mstn-ant4-
treated wounds showed a higher expression of fibromodulin in the early stages 
(Figure 3.9 A). However, this difference was not significant, except on day 7 by 
ITP t-test (p=0.01, not shown on figure). A similar trend is seen in uninjured skin 
where, Mstn-ant4 treatment results in a 3.8-fold (p=0.01, ANOVA) increase in 
fibromodulin expression. By day 7, the difference is 2.6-fold and borderline 
significant (p=0.066) (Figure 3.9 B). 
 
3.4.6 Gene expression ratios 
Two gene expression ratios were considered important in the context of this 
study. The ratio of TGF-β isoforms 1 and 3 are considered to be a more important 
factor in scarless wound healing than absolute amounts of any individual form 
(Hantash et al. 2008). Regarding TGF-β isoform ratios in the present study, there 
is a general increase in the ratio of TGF-β1:TGF-β3 at the 4 time points studied, 
possibly owing to the more rapid decline of TGF-β3 compared to TGF-β1 over 
that time period for all treatments/manipulations (Figure 3.10 A & B).  
 
The ratio of decorin to TGF-β1 expression can be indicative of the levels of 
decorin available to neutralise TGF-β1. There is no significant difference in the 
ratio of decorin to TGF-β1 over the time points studied between any combinations 
of treatment/manipulation, except on day 4 for saline-treated uninjured skin. The 
ratio for this time point shows 4-fold more decorin than TGF-β1 expression 
(Figure 3.10 C & D). This could be explained by the significant lag in TGF-β1 
expression for uninjured skin observed on this day (see Figure 3.6 B). 
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Figure 3.9: Fibromodulin expression 
A: Fibromodulin (Fmod) expression in burned skin for each treatment displayed 
as loge concentration values relative to house-keeping gene Histone H3.3A. B: 
Fibromodulin expression in control skin for each treatment displayed as loge 
concentration values relative to house-keeping gene Histone H3.3A. Error bar for 
both plots represents pooled standard error of the difference between means 
(SED). For all points, n=6 except SAL day 7 where n=5. 
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Figure 3.10: Gene expression ratios 
A & B: TGF-β1 expression as a ratio to TGF-β3. Loge values are used for ratio 
calculation. Error bar represents pooled standard error of the difference between 
means (SED). For all points, n=6 except SAL day 7 where n=5. C & D: Decorin 
expression as a ratio to TGF-β1. Loge values are used for ratio calculation. Error 
bar represents pooled standard error of the difference between means (SED). For 
all points, n=6 except SAL day 7 where n=5. 
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3.5 Histology 
The devastating effect of the burn injury can be seen clearly by trichrome staining 
of sections. This devastation, it would appear, can cause various patterns of 
regeneration. This variation made it difficult to make consistent measurements, 
particularly with respect to wound area. Re-epithelisation occurred sometime 
between days 7 and 14 for both treatment groups and therefore could not be 
assessed, as no histological data was available between these time points. 
Therefore, histological analyses were restricted to days 14 to 28, as all wounds 
had fully healed by day 35. The measurements made on sections from days 14 to 
28 included measurements of wound depth or granulation tissue thickness, 
wound width or granulation tissue width, and epidermal thickness over the wound 
area.  
 
Wound depth or granulation tissue thickness was significantly less in Mstn-ant4-
treated wounds (p=0.031, Figure 3.11 A) on day 14 but this significance 
disappeared on subsequent days. There was also significance in wound or 
granulation tissue width measurements for day 14 (p=0.003) where Mstn-ant4-
treated wounds were wider (Figure 3.11 B), but again results were not significant 
on subsequent days. Wound width measurements were made as an indication of 
wound contraction as in Fukai et al. (2005). This revealed that Mstn-ant4-treated 
wounds had contracted to a lesser degree than saline-treated wounds. It should 
be noted that values could not be obtained for all skin samples due to the quality 
of some tissue sections. The wounds of three animals were deemed to be fully 
healed by day 28 (one Mstn-ant4-treated and two saline-treated) and were not 
included in the analysis for day 28. One specimen was removed from the study at 
day 14 due to an unusual healing pattern; this was possibly the result of an 
infection which presented with granulation tissue development outside the 
original wound area. Figure 3.12 shows representative skin sections from the 
time points studied for each treatment. 
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Figure 3.11: Histology – granulation tissue thickness and width 
A: Granulation tissue thickness from days 14 – 28 measured in micrometers using 
Image-Pro Plus. B: Granulation tissue width from days 14 – 28 measured in 
micrometers using Image-Pro Plus. Errors for both plots represent individual 
SEDs. For both plots, day 14: Mstn-ant4 n=5, SAL n=4; day 21: Mstn-ant4 n=5, 
SAL n=4; day 28 Mstn-ant4 n=4, SAL n=3. 
** 
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Figure 3.12: Representative images of trichrome stained sections; days 14-28. 
Sections stained using modified Gomori‘s Trichrome showing collagen stained 
green, muscle and keratin (epidermis) red and nuclei dark red/black. Differences 
in wound contraction more pronounced on day 14. Scale bar = 1000 µm 
  
Day 14 - Saline Day 14 - Mstn-ant4 
  
Day 21 - Saline Day 21 - Mstn-ant4 
  
Day 28 - Saline Day 28 - Mstn-ant4 
 
Uninjured skin 
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4 DISCUSSION 
Solid evidence for the involvement of myostatin in the biology of skin is non-
existent. A PubMed search which combines the search terms ‗myostatin‘ and 
‗skin‘ retrieved two results, both of which refer to fish (Radaelli et al. 2003; 
Patruno et al. 2008). Fish usually have two myostatin genes which are expressed 
in many tissues, but as yet are functionally poorly defined (Rodgers et al. 2007). 
In 1997 the function of GDF-8 was discovered and appropriately named 
myostatin (McPherron et al. 1997). Like myostatin, many genes are given names 
according to their initially discovered function. Often this has meant that almost all 
successive research has been limited to the gene‘s function as dictated by the 
name. For some genes, other, sometimes more important functions, are 
subsequently discovered, regularly leading to confusion, and occasionally a 
name change is required. Therefore myostatin could have additional functions 
other than those already documented and reviewed by Bass et al. (1999), 
Sharma et al. (2001), Lee (2004), Patel and Amthor (2005), and McFarlane et al. 
(2008). The therapeutic potential of blocking myostatin to alleviate muscle 
wasting disorders has also been specifically reviewed (Tsuchida 2004; Bishop et 
al. 2005; Patel and Amthor 2005; McFarlane et al. 2008). Consequently, the main 
hypothesis of this study; that antagonism of myostatin can improve burn-wound 
healing in skin, falls outside the scope of research on myostatin to date. However, 
the formulation of this hypothesis is founded on several converging lines of 
evidence which are worthy of the brief discussion that follows. 
 
Although myostatin‘s main organ of expression is skeletal muscle, one of the 
unsolved issues with myostatin is the extent and locality of its distribution in active 
form. Inactive (latent) myostatin is present in serum (Patel and Amthor 2005) and 
recent evidence shows that the active form of myostatin is secreted into the 
circulation (Hosoyama et al. 2006). This is underlined by observations that 
circulating myostatin is increased in aged men and women suffering sarcopenia 
(Yarasheski et al. 2002) and in HIV-infected men with muscle wasting (Gonzalez-
Cadavid et al. 1998). This, together with the fact that cachexia can be induced by 
systemically administering myostatin (Zimmers et al. 2002), reveals a hormone-
like endocrine behaviour for circulating myostatin. 
 
The role that myostatin plays in tissues other than muscle hasn‘t yet been 
uncovered (Bishop et al. 2005). It is well known that myostatin signals through 
ActRIIB receptor together with ActRIB/TβRI (ALK4/ALK5), and it is likewise 
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established that all known activin receptors are expressed in both the 
mesenchymal and epithelial compartments of normal and wounded skin (Wankell 
et al. 2001). Therefore, with the presence of active form myostatin in the 
circulation, and the availability of receptors in skin, there is substantial potential 
for an important function for myostatin in skin. 
 
Myostatin is now also recognised as a factor in wound healing. This has been 
reviewed in chapter 1 so a brief summary will suffice here. Myostatin negatively 
regulates adult myogenesis and muscle regeneration from injury (Kirk et al. 
2000), and can impair macrophage and myoblast chemotaxis (McCroskery et al. 
2005), but is chemotactic for fibroblasts in vitro (Kambadur et al. 2006a). 
Enhanced regeneration and reduced fibrosis are seen in myostatin-null mice 
(McCroskery et al. 2005) and in mice treated with a myostatin antagonist after 
muscle injury (Kambadur et al. 2006c; Siriett 2007; Nozaki et al. 2008). In the 
absence of myostatin, a resulting increase in decorin leads to reduced scar tissue 
formation after muscle injury, suggesting that myostatin negatively regulates 
decorin expression (McCroskery et al. 2005). Decorin is known to neutralise TGF-
β, and in a similar way decorin binds and neutralises myostatin sequestering it 
into the ECM (Miura et al. 2005), as well as directly affecting its activity (Kishioka 
et al. 2008). Myostatin directly stimulates muscle fibroblast proliferation and 
expression of extracellular matrix proteins (Li et al. 2008). In addition, muscle 
fibroblasts express functional myostatin, which signals through the ActRIIB 
receptor inducing fibroblast proliferation via the canonical Smad pathway (Li et al. 
2008). 
 
Apart from these studies, work completed in this lab has specifically established 
the efficacy of Mstn-ant4. This particular myostatin antagonist has been shown to 
positively affect myoblast proliferation, as well as chemotaxis of macrophages, 
myoblasts, muscle fibroblasts, and dermal fibroblasts. It also affects myostatin 
signalling by competitive inhibition (Kambadur et al. 2006a; Kambadur et al. 
2006b; Kambadur et al. 2006c). 
 
The findings mentioned above provide a strong rationale for research focussing 
on the role of myostatin in skin wound healing. A further reason for the research 
was to specifically test whether a myostatin antagonist could improve skin wound 
healing for the purpose of satisfying wound healing and myostatin antagonist 
patents. The reason for this was to establish the commercial value of myostatin 
antagonist Mstn-ant4 developed at AgResearch for Orico Ltd. This research was 
conducted by analysing the effect of antagonising myostatin via systemic 
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administration of a Mstn-ant4 as a means to improve skin healing from burn 
wounds by reducing scar tissue formation. 
 
Currently, there are no prescription therapeutics available for the prevention or 
treatment of dermal scarring, and existing treatments are unreliable and 
unpredictable (Ferguson and O'Kane 2004; Hantash et al. 2008). Wound healing 
is an intricate and highly orchestrated process, involving complex interplay 
between cell influx into the wound bed, environmental factors in the surrounding 
skin, and various cytokine mediators (Aarabi et al. 2007). This is likely a good 
reason why there has been limited success in the treatment of scarring. Therefore 
the task of identifying possible anti-scarring treatments can be extremely 
challenging. 
 
Strategies to reduce scarring have focused on inhibiting collagen deposition, 
either directly by impeding synthesis, or indirectly by blocking TGF-β pathways 
(Tandara and Mustoe 2008). A discussion of the myostatin antagonist effect on 
collagen deposition and TGF-β expression will be followed by a discussion of its 
effects on other wound healing genes of interest such as SLRPs, and finally 
some ideas on a possible mechanism of action for the antagonist. 
4.1 Effect of myostatin antagonist administration 
Collagen 
Collagen type I predominates in normal human skin and exceeds collagen type III 
by a ratio of at least 4:1. During wound healing, this ratio decreases to 2:1 
because of an early increase in the deposition of collagen type III (Fathke et al. 
2004). These ratios are usually obtained by measuring the two different collagen 
protein types in a sample. In this study, total collagen was quantified using the 
hydroxyproline assay. Although this method does not distinguish between 
collagen types I and III, it is employed by most wound healing/scarring studies 
together with collagen mRNA expression data. Collagen expression 
measurements by RT-PCR represent amplified mRNA of collagen types I and III, 
and therefore correspond to gene expression levels of respective collagens. 
When viewing gene expression and protein data together, it should be 
acknowledged that gene expression doesn‘t necessarily correspond to protein 
translation and that amplified mRNA may not reflect actual mRNA because of 
assumptions about PCR efficiency (Wadenback et al. 2005). However, many 
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studies validate the use of collagen expression data to discuss the relative 
proportions of the collagen types, as is the case with this study. 
 
Type III collagen is seen as important for rapid tissue regeneration because of its 
ability to form intermolecular disulfide bridges which are assumed to be 
favourable to tissue regeneration (Masuda et al. 2002). Type III collagen is 
therefore considered a marker of early wound repair processes (Davidson 2001). 
As healing proceeds, the proportion of type I collagen increases with a 
corresponding decrease in the proportion of type III collagen, proteoglycans, and 
water (Baum and Arpey 2005). This occurs during the remodelling phase where 
type III collagen is replaced by type I, (which becomes divalently and trivalently 
cross-linked (Barnard et al. 1987)), restoring the normal dermal collagen profile 
(Kwon et al. 2007). Remodelling can take up to a year or more (Li et al. 2007), but 
it is assumed that the COL1:COL3 ratio normalises quite rapidly during the 
remodelling phase (Robins et al. 2003). In contrast, burn-injured dermal tissue 
contains significantly increased amounts of collagen III (Ulrich et al. 2002), and 
this may cause delays in normalisation of the collagen ratio. Garcia-Filipe and 
colleagues (2006) suggest that collagen III may be a marker for the extent of 
fibrosis by citing that the presence of a relative increase in collagen III is often 
associated with fibrosis and excessive scarring in many diseases. Garcia-Filipe et 
al. (2006) coined the term ―fibrotic index‖ where as a ratio, collagen III production 
is expressed relative to collagen I production. In the present study, there appears 
to be no significant difference in either collagen I or collagen III expression 
respectively between Mstn-ant4-treated and saline-treated groups. However 
when collagen I and III are viewed proportionally to each other as a ratio (fibrotic 
index), an interesting trend emerges. While initially there is no difference in 
COL1:COL3 between saline and Mstn-ant4-treated mice, by day 21 the ratio is 
significantly lower in Mstn-ant4-treated burns than saline-treated burns. This 
indicates that collagen III expression remains higher relative to collagen I 
expression for longer in Mstn-ant4-treated healing burn wounds. Therefore, 
according to Garcia-Filipe‘s et al. (2006) fibrotic index, Mstn-ant4-treated burn 
wounds may be at higher risk of progressing to a fibrotic state. However, this 
assumption is controversial, because of the role of collagen III in scarless foetal 
wound healing. 
 
Studies in foetal wound healing suggest that a difference in collagen-type 
deposition contributes to scarless healing. Collagen I is the main type in both 
foetal and adult skin, but foetal skin contains a higher proportion of type III than 
adult skin. In human foetal skin, collagen type III comprises 30% to 60% of the 
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total, whilst in adult skin it comprises 10% to 20% (Bullard et al. 2003; Baum and 
Arpey 2005). During development, the COL1:COL3 ratio in foetal skin increases 
approaching that of adults, correlating with the transition from scarless repair to 
scar formation after wounding (Bullard et al. 2003). In early adult wound healing, 
type III collagen is increased to about 30% (Baum and Arpey 2005), but in 
contrast, foetal wounds comprise significantly more type III than type I collagen 
(Beanes et al. 2003). The strength of type I collagen fibres relies on the formation 
of covalent cross-links. A predominance of non-cross-linked collagen type III in 
early foetal wounds might allow for a more flexible matrix, contributing to scarless 
repair in this manner; but it remains unknown whether scar formation is caused 
by a higher proportion of type I cross-linked collagen or whether a higher 
proportion of type I cross-linked collagen is caused by scar formation (Bullard et 
al. 2003). When collagen I:III ratios are viewed in this light, it seems that a higher 
proportion of type III collagen may contribute to reduced scarring, and this 
supports the proposition that Mstn-ant4 treatment may result in reduced scarring. 
 
In view of the total collagen estimation data, there appeared to be a non-
significant trend from day 14 to 21 where total collagen amounts were lower in 
Mstn-ant4-treated burn skin than saline-treated skin. However a reversal of this 
trend was seen on day 28, where the opposite effect was seen at a significant 
level. It might be tempting to suggest that the antagonist was causing the 
potentially fibrotic effect seen on day 28, but since administration of the 
antagonist had ceased by day 15, it is more likely that the result from day 28 
reflects a rebound compensatory effect which resulted in extra collagen being laid 
down to balance the previous deficit caused by the antagonist. By day 46, there 
was no significant difference in collagen amount in burned skin of either 
treatment. This observation suggests that a longer treatment regimen of the Mstn-
ant4 antagonist should be implemented. 
 
Histologically, new collagen deposition resulting in scar tissue could be identified 
by a deeper degree of staining of the affected area as well as a general absence 
of cutaneous structures, at later stages of healing. In the earlier stages of healing, 
the injured area was dominated by granulation tissue, which stained with a 
reduced intensity to the surrounding intact ECM. Granulation tissue was gradually 
replaced by collagen fibres up to day 28, after which the staining intensity of the 
affected area was comparable to normal dermis. The area of granulation/scar 
tissue is a combination between collagen deposition and wound contraction. 
Therefore, a small scar area is likely due to increased wound contraction rather 
than decreased collagen deposition, which is why hydroxyproline and collagen 
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expression data are important. There was large within-group variation in many of 
the histological measurements, which is a reflection of the magnitude of tissue 
damage caused by the burn injury, resulting in variation in regeneration patterns 
from animal to animal. 
TGF-β 
TGF-β1 affects all phases of healing and is clearly pro-fibrotic when added 
exogenously to foetal and adult wounds (Bullard et al. 2003). Three isoforms of 
TGF-β have been identified in mammals. The most abundant isoform, TGF-β1, is 
known to cause an increase in collagen gene expression and protein deposition 
(Beanes et al. 2003). TGF-β1 also reduces matrix degradation through inhibition 
of MMPs via increased expression of TIMPs (Bullard et al. 2003). Furthermore, 
TGF-β1 is chemotactic for fibroblasts and macrophages and enhances 
angiogenesis (Sporn and Roberts 1992). In this study, expression levels of TGF-
β1 between saline and Mstn-ant4-treated burns were indistinguishable over the 
time points studied, a result which leaves little to be discussed except that it fits 
well with the observation that there were no significant differences in collagen 
expression either, given TGF-β1‘s influence on collagen expression. However, 
there was a significant increase in TGF-β1 response in saline-treated uninjured 
skin compared to Mstn-ant4-treated skin on day 4. Whether this result has an 
effect on wound healing, will be discussed later. 
 
In contrast to TGF-β1, TGF-β3 has been suggested as an anti-scarring factor 
(see Table 4.1). Neutralisation of TGF-β1 and TGF-β2 has a similar effect to 
exogenous addition of TGF-β3 to cutaneous rat wounds in reducing scarring 
(Shah et al. 1995). Another of TGF-β3‘s functions might include the inhibition of 
inflammation (Rundle et al. 2005). Even though TGF-β1 is also present in foetal 
wounds, albeit transiently, scarless repair still occurs (Rolfe et al. 2007). This 
suggests that the relative proportion of isoforms is more important than the 
absolute amounts of any one form (Dang et al. 2001; Colwell et al. 2003). One of 
the reasons for a difference in expression profiles of TGF-β isoforms is that TGF-
β3 is produced mainly by keratinocytes and fibroblasts, whereas TGF-β1 and 
TGF-β2 are initially sourced from degranulating platelets, and later from 
monocytes, macrophages, and fibroblasts (Ferguson and O'Kane 2004; Miller 
and Nanchahal 2005). Interestingly, the clinical potential of TGF-β3 as an anti-
scarring agent has been recognised and it has recently entered phase II clinical 
trials in humans for scar prevention and/or reduction (Hantash et al. 2008). 
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Table 4.1: Summary of the evidence for the central role of TGF-β3 in scarring 
 present at high levels in developing skin and in embryonic wounds that heal with 
no scar 
 present at low levels in adult skin and wounds that scar 
 induced late in adult wound healing when levels of TGF-β1 start to fall 
 neutralisation of TGF-β3 in adult wounds makes the scar worse 
 addition of TGF-β3 to adult wounds reduces or eliminates scarring 
 genetic deletion of TGF-β3 causes scarring following embryonic wounding (litter 
mate +/+ embryos heal with no scar) 
(from Ferguson and O'Kane 2004) 
 
In the present study, like TGF-β1, the expression of TGF-β3 showed little 
variance between treatments in burned skin. However, also like TGF-β1, the 
significant (p=0.001) increase (6.1-fold) in Mstn-ant4 treated skin was seen in 
uninjured skin on day 4. Because TGF-β3 is expressed at a higher level than 
TGF-β1 (6.1 vs 4.1-fold), the ratio of TGF-β3:TGF-β1 is important when 
considering whether TGF-β3 is going to have any anti-scarring effect. In this 
study, the relative proportion of TGF-β3 is higher than TGF-β1 at day 4 in 
uninjured skin of Mstn-ant4-treated mice, although this difference (p=0.1) is not 
considered significant. 
Decorin 
Decorin is the predominant proteoglycan in skin (Sayani et al. 2000) and is 
therefore worthy of study in any wound healing context. Indeed, decorin has been 
implicated as an anti-fibrotic factor in wound healing and therefore, its up-
regulation in this study would be indicative of an anti-fibrotic activity for the 
myostatin antagonist. It is well-established that decorin binds TGF-β via its core 
protein (Yamaguchi et al. 1990) and this binding neutralises all three TGF-β 
isoforms (Hildebrand et al. 1994). It likely acts by sequestering TGF-β, while itself 
is bound to the ECM (Markmann et al. 2000). This appears to be a legitimate 
function of decorin as part of a negative feedback loop that regulates TGF-β 
activity, and, since the binding of decorin to TGF-β is reversible, any TGF-β 
bound to it in tissue forms a reservoir of the growth factor (Ruoslahti and 
Yamaguchi 1991). The TGF-β-binding property of decorin has been used to 
prevent fibrosis in several studies (Border et al. 1992; Giri et al. 1997; Fukushima 
et al. 2001; Shimizu 2001; Sato et al. 2003; Li et al. 2004; Grisanti et al. 2005; 
Huijun et al. 2005). Interestingly, decorin also binds myostatin and suppresses its 
activity in myogenic cells (Miura et al. 2005; Kishioka et al. 2008), and myostatin-
 104 
 
null mice show increased expression of decorin mRNA, reduced fibrosis and 
improved healing (McCroskery et al. 2005). In addition, decorin has been shown 
to up-regulate the expression of follistatin, a natural antagonist of myostatin (Zhu 
et al. 2007). Consequently, it is possible for any anti-fibrotic effect of antagonising 
myostatin to be potentiated by an up-regulation of decorin.  
 
In this study the greatest effect of the antagonist on decorin expression was seen 
on day 7 where it induced a significant 2.1-fold increase (p=0.007, ITP t-test) in 
uninjured skin and a 1.4–fold increase in burn skin, which bordered on 
significance (p=0.056). The effect observed in uninjured skin would seem to 
correlate with the increase in water content of uninjured control skin between 
days 7 and 21.  
 
Even though studies of foetal wound healing reveal that decorin is down-
regulated during the gestational age when scarless healing occurs (Beanes et al. 
2001), decorin‘s importance in adult wound healing for preventing fibrosis should 
not be underestimated (Yamaguchi et al. 1990; Border et al. 1992; Costacurta et 
al. 2002; Jahanyar et al. 2007; Zhu et al. 2007). Furthermore, hypertrophic scars 
exhibit a marked lack of decorin (Scott et al. 1996; Sayani et al. 2000), and 
therefore restoring decorin levels could be one possible application of the 
antagonist treatment, as decorin treatment inhibits cell proliferation and down-
regulates TGF-β1 production in hypertrophic scar fibroblasts (Zhang et al. 2007). 
In addition, decorin‘s appearance in burn wounds is delayed (Sayani et al. 2000), 
so the early induction of decorin in Mstn-ant4-treated skin compared with saline-
treated skin could be another important function of Mstn-ant4 in burn wounds.  
 
One striking observation with all gene expression data is that where significant 
increases in gene expression occured in the early stages of wound healing in 
antagonist treated skin, they had largely disappeared by day 14. During the trial, 
mice were injected with either saline or Mstn-ant4 on days 1, 3, 5, 7, 10, and 15. It 
is therefore noteworthy that during the first week after wounding, injections were 
more frequent than after day 10. Therefore, the decrease in frequency of injection 
coincides with a loss of the effect that is seen by antagonist administration on 
earlier time points when injections were more frequent. Consequently, if the 
frequency of treatment given in the first several days was maintained for several 
weeks, then the significant differences observed in the early stages of healing 
may also be maintained for longer. 
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Fibromodulin 
Post-translational modifications of fibromodulin clearly distinguish it from decorin 
(Hocking et al. 1998). Both decorin and fibromodulin bind to active TGF-β 1, 2 
and 3 via their core proteins, however, the chondroitin/dermatan sulfate chains of 
decorin appear to hinder this binding, making TGF-β1 binding to fibromodulin 
more effective than to decorin within the tissue (Hildebrand et al. 1994; Burton-
Wurster et al. 2003). In addition, fibromodulin can bind (though slightly) TGF-β1 
precursor whereas decorin cannot (Hildebrand et al. 1994). In contrast to decorin, 
fibromodulin decreases with increasing gestational age in foetal skin. A study in 
rats by Soo et al. (2000) clearly outlines contrasting aspects between decorin and 
fibromodulin. They observed that decorin was up-regulated during adult wound 
healing whereas fibromodulin expression was initially down-regulated. They also 
observed that fibromodulin is significantly up-regulated in gestation day-16 foetal 
wounds, but not in gestation day-19 wounds, which is generally observed to be 
the transition time point between scarless and scar-forming foetal wound healing 
in rats. They also note that scarless foetal wound healing occurs despite the 
presence of TGF-β and that the observed down-regulation of fibromodulin in adult 
wound healing allows increased activity and auto-induction of TGF-β, which may 
lead to scar and/or fibrosis. These observations strongly implicate fibromodulin as 
an anti-fibrotic agent. There are a few findings that may shed light on 
fibromodulin‘s anti-fibrotic properties.  
 
TGF-β1 is rapidly induced in mouse embryo (E11.5) wounds, but is also rapidly 
cleared within 18 hours (Martin et al. 1993). In association with elevated 
fibromodulin levels, this may decrease overall TGF-β bioavailability (Soo et al. 
2000; Stoff et al. 2007), leading to decreased ECM deposition and therefore 
decreased scarring. Stoff et al. (2007) reported that over-expression of 
fibromodulin induced a decrease in expression of TGF-β1 and TGF-β2 precursor 
proteins, and an increase in expression of TGF-β3 precursor protein and TGF-β 
type II receptor in cell culture. As a result, they showed that fibromodulin over-
expression improves wound healing in vivo. Moreover, while fibromodulin can 
bind activated TGF-β and suppress TGF-β activity, with fibromodulin exhibiting 
the greatest affinity for TGF-β1, as well as the latent TGF-β1 precursor, 
fibromodulin appeared to be a less effective binder of TGF-β3 than decorin 
(Hildebrand et al. 1994). This is significant because of TGF-β3‘s association with 
scarless foetal wound healing. It is also significant because, assuming most of 
the TGF-β1 mRNA was translated to protein, TGF-β1 protein could be 
sequestered by fibromodulin in the ECM, thereby neutralising its fibrotic ability. 
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In the present study, there were observed increases in fibromodulin expression in 
both burned and uninjured Mstn-ant4 treated skin at day 4, which remained 
significantly increased by day 7 (p=0.01, individual t-test). Again, like decorin and 
TGF-β, differences in fibromodulin expression had disappeared by day 14 
suggesting that while the antagonist is available in the circulation, it can induce 
favourable gene expression patterns for improved wound healing. 
 
Skin hydration 
The observation that the skin of antagonist-treated mice contained a significantly 
higher percentage of water, as determined by weight, up to one week after the 
treatment regime ended is strong evidence for the positive effect of the antagonist 
on skin hydration levels, and once again suggests that a longer injection period 
would allow this effect to persist. It seems intuitive that proper hydration is 
essential for proper wound healing, but very little research has been conducted to 
support it. Adequate systemic hydration is important for maintaining blood volume 
and pressure and therefore sufficient nutrient and oxygen delivery. But at a local 
level, it may be that increased water content is the secondary result of the 
presence of other essential skin constituents for wound healing. The fluid content 
of skin is determined by proteoglycans, and their polysaccharide side chains 
called GAGs. As mentioned in the section 1.1.2, GAGs are strongly hydrophilic. 
Their strong negative charge attracts osmotically active Na+, causing large 
amounts of water to be drawn into their structure (Chakravarti et al. 1998; Schultz 
et al. 2005). Hyaluronate is the most abundant GAG in skin and is important in 
wound healing processes, such as inflammation, for its role in stimulating 
inflammatory cytokines and cellular infiltration into the provisional wound matrix, 
as well as stimulatory effects of angiogenesis and re-epithelialisation (Chen and 
Abatangelo 1999). Foetal skin is known to have a high proportion of hyaluronate 
in place of collagen and fibroblasts are also known to have increased density of 
hyaluronate cell surface receptors, which may be linked to foetal skin‘s scarless 
healing ability (Manuskiatti and Maibach 1996). Although hyaluronate content 
was not a subject of this study, it could be an interesting future direction. On the 
other hand, the proteoglycan decorin was a subject of this study and it too has 
water retentive ability. As was shown, decorin was significantly up-regulated in 
antagonist-treated skin on day 7. Subsequent protein analysis may have 
confirmed the presence of increased amounts of actual decorin protein, and this 
may have correlated with the elevated water content observed in Mstn-ant4-
treated skin, which persisted until day 21, while differences in decorin expression 
levels seemed to be gone by day 14.  
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Fibromodulin, which is similar to decorin, was also significantly up-regulated on 
the seventh day following injury in Mstn-ant4-treated skin. The observed water 
retention is likely a downstream effect of both decorin and fibromodulin 
expression. In further support of a role for fibromodulin in tissue hydration, it has 
been shown to determine stroma matrix structure and fluid balance in 
experimental carcinoma (Oldberg et al. 2007). 
 
Epidermal hydration is determined by the intracellular water content of 
keratinocytes. Aquaporins are proteins that facilitate water transport across cell 
membranes (Dumas et al. 2007) and are believed to be important in wound 
healing, by facilitating cell migration, and enhancing keratinocyte proliferation and 
differentiation (Boury-Jamot et al. 2009). Tandara and colleagues (2007) have 
shown that hydrated keratinocytes reduce collagen synthesis by fibroblasts via 
paracrine mechanisms in co-culture. If this effect occurs in vivo, the result would 
be decreased collagen deposition and therefore reduced scarring (Tandara and 
Mustoe 2008). Because hydration modifies the levels of cytokines keratinocytes 
secrete, it has been shown by the same lead author in another study that the 
reduced collagen content of the keratinocyte-fibroblast co-culture was likely due 
to a large increase in MMP activity (Tandara et al. 2004). Keratinocyte hydration 
also seems to be important for other aspects of wound healing. Re-
epithelialisation is aided by hydration via keratinocyte differentiation with faster 
skin barrier reformation and recovery (Dumas et al. 2007). It is likely that in the 
present study, increased skin hydration in Mstn-ant4-treated mice was due to 
increased secretion of proteoglycans and their associated GAG chains. However, 
one could speculate that a well-hydrated dermis could also influence the 
hydration of the epidermis, and produce the favourable effects on fibroblasts seen 
when well hydrated keratinocytes are present. 
 
It has been observed that major changes in the properties of skin occur as a 
result of aging, and this in turn has a major effect on wound healing. Among those 
changes are: decreased keratinocyte maturation, decreased fibroblast 
proliferation, flattening of dermis and dermal/epidermal junction, reduced 
sebaceous and sweat gland activity, and decreased vascularity (Worley 2006). A 
decrease in dermal hydration results either directly or indirectly from these 
changes. It has also been established that an age-related change in 
proteoglycans occurs. Carrino and others (2000) report that as a function of age, 
there is a decrease in the proportion of large chondroitin sulfate proteoglycans 
(versican) and an increase in the proportion of small dermatan sulfate 
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proteoglycans (decorin). Interestingly, they elaborate on decorin by documenting 
that foetal decorin is slightly larger than adult decorin and that a proteoglycan 
which is smaller than decorin, but has the same terminal amino acid sequence, is 
abundant in mature skin. They speculate that this decorin analogue may affect 
normal decorin‘s ability to modulate collagen fibrillogenesis, which may in turn 
affect skin elasticity (Carrino et al. 2000). In view of this, there could be some 
beneficial effect for the myostatin antagonist on aging skin. Antagonist-treated 
skin has significantly higher hydration levels, and this is likely due to up-regulation 
of proteoglycans such as decorin and fibromodulin. This could restore the 
balance of normal decorin in aged skin and by improving hydration in the skin of 
the aged may also elicit noticeable improvements in wound healing. In addition, 
since it has been shown that antagonising myostatin reduces age-related 
sarcopenia (Siriett et al. 2007), there could be a dual benefit in administering the 
myostatin antagonist to the aged. Furthermore, poorly hydrated skin seems to be 
considered by those in the industry as adversely affecting cosmetic appearance, 
making Mstn-ant4 a potential candidate for cosmetic applications. 
4.2 Consideration of cumulative evidence 
Before proceeding, the body of evidence should be considered in the context of 
some possible limitations of the study. One of the assumptions, and perhaps a 
limitation of this study, was the standardisation of the burn injury. There was a 
certain art in applying and maintaining constant pressure of the burn-causing 
implement by hand and this invites some human error and variability. With a burn 
injury, especially in the early stages, the majority of the area will consist of dead, 
necrotic tissue. Also, the regeneration of the wounded area will result in an 
induction of a massive gene expression program, on top of which any response to 
the Mstn-ant4 treatment will need to be detected, which may prove difficult, 
considering that even genes used as internal controls may vary under these 
circumstances (McKinnell et al. 2005). This may help explain why burned skin 
showed fewer and smaller significant differences in gene expression between 
treatments, whereas when there were differences, the significance was greater in 
uninjured skin at corresponding early stages of healing. For these reasons, it may 
be appropriate, and even insightful, to consider the genetic expression response 
to Mstn-ant4 treatment of uninjured tissue, which has not suffered the influence of 
a burn injury, as homeostatic skin would not be required to alter constitutive gene 
expression, in contrast to the enormous physiologic demand to which burn injured 
skin is prone. Therefore, if it was observed that certain genes important for wound 
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healing responded to Mstn-ant4 treatment in uninjured skin near the burn site, 
this may be informative of what is occurring at the burn site but which may be 
somewhat masked by the effect of the burn wound. Therefore, a future approach 
might be to excise the dead necrotic centre of the burn wound and analyse the 
tissue immediately surrounding the burn. Histological examination of the burn 
injury could still be used to ascertain morphological effects of treatment. In the 
present study, gene expression data from both injured and uninjured skin, 
together with histological analysis, is used to state the cumulative case for the 
improvement of wound healing in skin by the administration of a myostatin 
antagonist.  
 
Of considerable interest are the aspects of the evidence which relate to scarless 
healing in foetal wound healing studies. Antagonist-treated wounds had a higher 
proportion of type III collagen expression and a larger induction of fibromodulin 
and TGF-β3 expression at early time points. This could have been responsible for 
the significant reduction in wound contraction (p=0.03) and reduced granulation 
tissue thickening (p=0.003) seen at day 14. However, unlike foetal wounds, there 
was an increase in TGF-β1 in Mstn-ant4-treated uninjured skin, although this is 
inevitable in postnatal wound healing because TGF-β1 is initially released by 
degranulating platelets, which is lacking in foetal wounds (Ferguson and O'Kane 
2004). Also unlike foetal wounds decorin expression was significantly up-
regulated in Mstn-ant4 treated skin at day 7. While the TGF-β-binding anti-fibrotic 
effects of decorin are noteworthy and well documented, there is no evidence to 
suggest that decorin preferentially binds TGF-β1 over TGF-β3. So the anti-
scarring potential of TGF-β3 may be reduced by an increased presence of 
decorin. Having said this, the up-regulation of decorin expression in Mstn-ant4-
treated skin is still important because of its ability to bind and inhibit both TGF-β1 
and myostatin directly. Therefore, Mstn-ant4 may antagonise myostatin directly, 
and via decorin up-regulation, may cause further indirect antagonism of 
myostatin, as well as indirect antagonism of TGF-β1. Myostatin may also be 
further antagonised by decorin‘s ability to cause up-regulation of follistatin.  
 
The positive effect of the myostatin antagonist on body weight recovery, and skin 
hydration were unexpected, though significant findings of this study, because of 
their importance for wound healing. Another significant observation was that in all 
gene expression data and histology measurements where a significant effect of 
Mstn-ant4-treated skin was observed, this subsequently disappeared following a 
change in the frequency of, or complete withdrawal of treatment. This is evidence 
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that Mstn-ant4 was causing the observed effects. A summary of the evidence for 
Mstn-ant4 treatment to improve wound healing in skin is given in Table 4.2. 
 
Table 4.2: Summary of effects seen in Mstn-ant4 treated animals which are 
favourable to improved wound healing 
 Increased decorin expression 
 Increased fibromodulin expression 
 Increased TGF-β3 expression 
 Decreased COL1:COL3 expression ratio 
 Increased skin hydration 
 Decreased time until body weight recovery 
 Decreased granulation tissue contraction 
 Decreased granulation tissue thickness 
Possible mechanisms 
There are two main possibilities for a general mechanism. The first and most 
obvious mechanism to consider is that myostatin, and therefore the antagonist, 
has some direct effect on wound healing in skin. As in muscle, it may have some 
effect on macrophage and fibroblast chemotaxis and/or proliferation. The other 
possibility is that myostatin has some indirect effect on wound healing in skin. 
Since lack of myostatin results in an increase in decorin (McCroskery et al. 2005), 
this could improve wound healing via an effect on TGF-β. Alternatively, the 
antagonist could be affecting other wound healing related genes indirectly. These 
possibilities will be discussed further below. 
 
If in this study Mstn-ant4 is antagonising myostatin directly, then it may occur in 
two possible ways. One possible mechanism is that Mstn-ant4 binds to, and 
occupies, the ActRIIB receptor in competition with myostatin. The other is that 
Mstn-ant4 may bind to myostatin, preventing its binding to the receptor. The 
tertiary structure of the myostatin antagonist Mstn-ant4 is likely to be quite 
different from mature myostatin, because Mstn-ant4 lacks four of the six cysteines 
required to form the typical growth factor cystine knot (see Figure 4.1 A). It is not 
clear whether the cystine knot would be required for receptor binding or for 
binding to myostatin, although the BMP antagonist Noggin contains a cystine knot 
topology similar to that of BMPs (Groppe et al. 2002). Berry et al. (2002) have 
shown that in Piedmontese myostatin, substitution of cysteine with tyrosine 
results in modification of the cystine knot structure such that the resulting altered 
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structure of mature myostatin acts in a dominant negative fashion inhibiting 
normal myostatin function in vitro. A myostatin splice variant (MSV), whose 
mature form also has fewer cysteines than myostatin, antagonises myostatin in a 
similar manner (McMahon pers. comm.). Moreover, evidence suggests that MSV 
can bind receptors and elicit its own unique signal in competition with myostatin 
(McMahon pers. comm.). Recent work in this lab has attempted to shed light on a 
possible mechanism of action for Mstn-ant4. Binding assays were conducted 
which included binding radio-labelled Mstn-ant4 to ActRIIB, and radio-labelled 
Mstn-ant4 to recombinant myostatin. A strong concentration-dependent effect 
was seen from the assay with the Mstn-ant4 bound to ActRIIB and it seems that 
Mstn-ant4 also binds myostatin albeit to a lesser degree of affinity than to ActRIIB 
(Hennebry and Plummer unpublished observations). 
 
Regarding the possible mechanism for the antagonist binding to and 
sequestering myostatin, Huang (2002) and colleagues examined the effect of a 
synthetic TGF-β peptide antagonist which had an amino acid sequence identical 
to residues 41–65 of mature TGF-β1 (see Figure 4.1 B). Its effect on wound 
healing was studied in a pig model using a standardised burn injury. They 
successfully showed accelerated wound healing and reduced scarring. 
Unfortunately, they did not discuss a possible mechanism of action for the 
peptide antagonist. The primary structure of the peptide antagonist contains two 
cysteine residues and it may be more likely to bind TGF-β1 rather than bind to 
TβRII receptor, because its sequence doesn‘t contain the putative receptor 
binding residues R94 and R25 of mature TGF-β1 (Shimanuki et al. 2007). Both 
active myostatin and active TGF-β1 occur naturally as dimers. This dimeric 
association becomes stable by hydrophobic interactions and is usually further 
stabilised by an inter-subunit disulfide bridge (Lin et al. 2006). TGF-β superfamily 
members activin, inhibin, and a few BMPs have been shown to form 
heterodimers, with evidence suggesting many heterodimers have more potent 
activity than corresponding homodimers (Lin et al. 2006). It seems possible that 
Mstn-ant4 could form a heterodimer with myostatin, and either inhibit myostatin 
from binding to the receptor, or increase myostatin‘s receptor binding capacity, 
and compete with normal myostatin. The primary structure of the Mstn-ant4 
antagonist consists of the first 44 amino acids identical to mature myostatin 
including four cysteine residues at positions 7, 16, 17, and 44 (Figure 4.1 A). 
Therefore, Mstn-ant4 could bind to mature myostatin in the same way that the 
TGF-β1 antagonist binds to TGF-β1 shown by Huang et al. (2002). There is a 
small overlap in sequence similarity between the TGF-β antagonist used in 
Huang et al. (2002) and the Mstn-ant4 antagonist used in this study. The 
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possibility that Mstn-ant4 may also dimerise with TGF-β1 is a possible 
mechanism of action worth considering. 
 
A comparison of myostatin and TGF-β may be useful in discussing the possibility 
that Mstn-ant4 could be directly affecting TGF-β. Budasz-Swiderska et al. (2005) 
and Kollias and McDermott (2008) provided constructive reviews of the 
similarities between myostatin and TGF-β which will be summarised below. While 
their observations concern the effects of myostatin and TGF-β on myogenic cells, 
there may be several of these aspects that apply to other types of cells, namely 
fibroblasts and keratinocytes, which share receptor-signalling properties with 
myoblasts. It is well noted firstly that TGF-β1 is much more pleiotropic than 
myostatin, and TGF-β1 activity is very specific to the cellular and intracellular 
context of the cell. The multi-faceted nature of TGF-β1 seems to be necessary for 
its in vivo function, since it regulates many tissues and processes (Kollias and 
McDermott 2008) by stimulating growth of the majority of the mesenchymal cells 
and inhibiting growth of epithelial, lymphoreticular, hematopoetic and endothelial 
cells. Myostatin is only regarded as an inhibitor of myogenic cell proliferation and 
differentiation (Budasz-Swiderska et al. 2005), and interestingly, TGF-β1 also has 
these effects on myogenic cells (De Angelis et al. 1998). The close structural and 
processing parallels between Myostatin and TGF-β have been alluded to in 
Chapter 1 and are further detailed in Figure 4.1. A sequence analysis reveals 
approximately 51% homology at the nucleotide level (34% at amino acid level, 
see Figure 4.1 C) between the functional domains of each polypeptide. The 
receptors and transcription factors used by myostatin and TGF-β1 in signal 
transduction pathways belong to the same families. Type II receptors for 
myostatin and TGF-β are ActRIIB and TβRII respectively. ActRIB (also known as 
ALK 4) is usually cited as the myostatin type I receptor, but both myostatin and 
TGF-β can signal through TβRI (also known as ALK 5) (Rebbapragada et al. 
2003; Budasz-Swiderska et al. 2005; Kollias and McDermott 2008). The same 
intracellular Smad proteins are involved in transmitting the signal to the nucleus. 
Finally Budasz-Swiderska et al. (2005) observed that the inhibition of myoblast 
proliferation and terminal differentiation by myostatin and TGF-β1 occurs through 
similar molecular mechanisms. In addition to the observations made by the above 
authors, Zhu et al. (2007) suggest that myostatin can also bind the TβRII receptor 
by observing that because TβRII-soluble receptor antagonises, at least in part, 
the effect of myostatin on muscle cells. This therefore allows for another possible 
mechanism of action, where the myostatin antagonist may be able to bind TβRII 
receptor, and inhibit TGF-β1 signalling, leading to improved wound healing. 
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If the antagonist is affecting TGF-β signalling, there should be some evidence of 
this with expression of collagen or even autocrine-directed expression of TGF-β 
itself. But both TGF-β1 and TGF-β3 are up-regulated by the antagonist at early 
time points in uninjured skin and there are only minor differences in collagen 
deposition between treatments, although this could be a limitation of the 
treatment regimen. Based on findings from this study and others (McCroskery et 
al. 2005; Zhu et al. 2007), it seems more likely that antagonism of myostatin 
causes decorin to be up-regulated, which in turn, sequesters TGF-β1, and this 
may be reflected in the histological observation that antagonist-treated wounds 
exhibited wound contraction to a lesser degree than saline-treated wounds. This 
effect may have been a result of decreased differentiation of fibroblasts into 
myofibroblasts. However blocking myostatin may also have had a similar effect 
(Zhu et al. 2007), although data from Artaza et al. (2008) suggests this is 
controversial. It should be noted also that decorin can neutralise the stimulatory 
effects of myostatin in fibroblasts (Zhu et al. 2007). Differences in granulation 
tissue width were significant in the wound area at day 14. This could result in 
decreased collagen deposition in response to neutralisation of TGF-β1. At day 
14, Mstn-ant4 treatment also resulted in less dermal thickening. The development 
of wound contraction force has been found to be proportional to the thickness of 
granulation tissue (Snowden and Cliff 1985), and the same correlation between 
decreased wound contraction and reduced granulation tissue thickness observed 
here, is also reported in other studies (Joseph et al. 1996; Joseph et al. 1997). 
Decreased wound contraction may cause wounds to heal over a longer period of 
time, but the ultimate result would be reduced scarring. The significance of the 
granulation tissue width and thickness differences had disappeared by day 21. 
Once again, the loss of significant differences from day 21 onwards could be a 
result of the response of the healing wound to withdrawal of treatment almost a 
week earlier, on day 15. 
 
It should be considered that antagonising myostatin may give rise to downstream 
effects on the expression of other genes. The powerful myogenic effect observed 
by blocking myostatin may even be in part due to the effect of inhibiting other 
genes that affect myogenesis such as TGF-β. In support of this idea, Se-Jin Lee 
(2007) recently showed that muscle mass was likely regulated by genes other 
than, but related to, myostatin, by over-expressing follistatin in myostatin-null 
mice to achieve a quadrupling of muscle mass.Another possibility is that 
myostatin antagonism may affect intracellular Smad signalling which both 
myostatin and TGF-β share. Wound healing studies which focus on Smads have
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Figure 4.1 Similarities between TGF-β superfamily members 
A: Mature myostatin with antagonist sequence indicated in boxed section. Cysteines highlighted yellow, cysteine bonds indicated which give rise to 
cystine knot. B: Mature TGF-β1 with peptide antagonist from Huang et al. (2002) indicated in box. C: Amino acid alignment between mature portions of 
myostatin and TGF-β1. D & E: similarities between type I and type II TGF-β superfamily member receptors, respectively (adapted from Massagué 
2000). F: Sequence similarities between TGF-β superfamily members (Lee 2004), notice that myostatin is very closely related to TGF-β.  
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shown they make a considerable contribution to wound healing (Ashcroft et al. 
1999; Ashcroft and Roberts 2000; Chong et al. 2007). This includes inhibitory 
Smads, such as Smad-7, which regulate both TGF-β and myostatin signalling 
(Zhu et al. 2004; Forbes et al. 2006). 
 
A consideration of other genes that could be suppressed by the antagonist 
rendering the ActRIIB receptor unavailable is worthy of discussion as far as they 
relate to wound healing. Activin binds to activin receptors and this factor is 
purported to have a role in wound healing. Activin stimulates fibroblasts to 
produce fibronectin and collagen in vitro, and mice over-expressing activin in the 
epidermis exhibit accelerated wound healing by enhanced granulation tissue and 
ECM deposition (Munz et al. 1999). In their study, Munz et al. (1999) showed that 
there was no significant difference in either collagen type I or type III expression 
in the over-expressing mice suggesting a different mechanism of activin-mediated 
ECM deposition to that of TGF-β, although like TGF-β, activin may still be a 
stimulator of fibrosis, as high levels of the cytokine are found in fibrotic (Munz et 
al. 1999) and chronically inflamed tissues (McLean et al. 2008). Therefore, there 
could be therapeutic potential in blocking activin signalling during wound healing, 
especially in burn wounds, which have a higher potential to become fibrotic. This 
could therefore be a beneficial mechanism of action for the antagonist. The 
therapeutic potential of activin antagonists have been recognised (Harrison et al. 
2005) and McLean et al. (2008) speculated that administration of follistatin, a 
natural activin (and myostatin) antagonist could be of therapeutic relevance here. 
However, a study conducted by Wankell and colleagues (2001) showed that over-
expression of follistatin in transgenic mice impairs wound healing. It should be 
noted though that while wounds took longer to heal and granulation tissue 
formation was significantly reduced, the resulting scar area was smaller than in 
controls. Therefore, from these complementary studies it can be inferred that 
over-expression of activin in the epidermis accelerates wound healing but 
increases scar formation, while inhibition of activin activity in the skin delays 
wound healing but improves the quality of the healed wound (Sulyok et al. 2004). 
Although completely blocking activin may not be the best approach to improve 
healing outcome, antagonising activin to some degree could have beneficial 
effects by preventing excessive matrix deposition. The myostatin antagonist could 
fulfil this role. If the antagonist has the same type II receptor binding 
characteristics as myostatin, which is high affinity for ActRIIB but lower affinity for 
ActRIIA (Lee and McPherron 2001), then this action would obstruct activin 
signalling through ActRIIB.  
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Bone Morphogenic Proteins (BMPs) are the largest subfamily of the TGF-β 
superfamily and play an important role in development and homeostasis of 
postnatal tissues. They are also implicated in some pathological states as well as 
wound healing (Botchkarev 2003). BMP-2 can signal through ActRIIB, although 
not with high affinity (Weber et al. 2007), and BMP-6 also makes use of ActRIIB 
to elicit its signal (Ebisawa et al. 1999). Research suggests that BMPs, like TGF-
β and activin have a role to play in the fibrogenic process. After both acute 
wounding and in chronic wounds, BMP-6 is up-regulated in keratinocytes and 
fibroblasts in skin, and delayed re-epithelialisation and scar formation is observed 
in BMP-6 over-expressing transgenic mice, suggesting that BMP-6 represses 
keratinocyte proliferation (Blessing et al. 1996; Kaiser et al. 1998). BMP-2 seems 
to induce scar formation in much the same way as TGF-β (Stelnicki et al. 1998; 
Botchkarev 2003). Therefore, by blocking activin receptor binding sites, Mstn-
ant4 may be able to antagonise BMPs 2 and 6 causing improvements in wound 
healing. 
 
In summary, the myostatin antagonist used in this study could be having its effect 
on wound healing in three possible ways. Firstly, Mstn-ant4 could be inhibiting 
myostatin directly, either by binding myostatin itself or competing with myostatin 
for its receptor, to prevent myostatin signalling. Secondly, Mstn-ant4 could be 
antagonising TGF-β1 by causing an up-regulation of decorin or by interfering with 
TGF-β1 signalling directly. Thirdly, by binding to and occupying ActRIIB cell 
surface receptors, other factors which use these receptors may be blocked from 
signalling, leading to improvements would healing. 
4.3 Concluding remarks 
Because of the complexity of the wound healing process and the interaction and 
synergism of several growth factors and cytokines, manipulating the wound 
environment to promote regeneration is a challenging prospect. At present, most 
therapies involve application of a single factor in the hopes that this will result in 
perfect healing, but mono-therapy is unlikely to be effective (Aarabi et al. 2007). 
Because foetal wounds heal with true tissue regeneration they represent the ideal 
model for wound repair. The fact that myostatin antagonist treatment in skin 
wound healing can produce up-regulation of several genes implicated in scarless 
foetal wound healing is indicative of its potential as a therapeutic agent. 
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4.4 Future directions 
The completion of this study has answered several pending questions and has 
provided a basis for future studies to be conducted. In particular, the main 
purpose of the study was two-fold: to develop an in vivo wound healing model 
with respect to burn wound healing in skin, and to assess the performance of the 
antagonist Mstn-ant4 in skin wound healing using the aforementioned in vivo 
model. Previously in this lab, myostatin antagonists Mstn-ant1 to 3 have been 
used in various acute and chronic muscle wasting conditions such as notexin and 
incision injury (acute), sarcopenia, and muscular dystrophy (chronic) models, with 
impressive results (Siriett 2007; Siriett et al. 2007). In acute trials, myostatin 
antagonist injections in the first few days after injury produced significant 
reductions in scar tissue formation after muscles were allowed to fully heal. The 
treatment regime for the present study was adapted from an acute muscle 
healing model. Results from this study now suggest that skin wound healing from 
a severe burn may benefit from a chronic wound healing treatment regime. In 
such a treatment schedule, the antagonist would be injected three times per week 
for the duration of the trial, instead of gradually reducing injection frequency from 
day 7 of the trial to end treatment by day 15. Since remodelling in skin continues 
for months to years, a greater benefit from the antagonist may be seen if 
treatment continued for longer than 15 days. 
 
Having now tested Mstn-ant4 in vivo, several in vitro methods could be employed 
to further study its effect on skin wound healing. In vitro assays involving 
proliferation and differentiation of keratinocytes, and dermal fibroblast 
differentiation into myofibroblasts could be employed. The purpose of these 
assays would be to study the effects of both endogenous and exogenous 
myostatin on these processes and whether they can be reversed by 
administration of Mstn-ant4. 
 
For the initial findings of this study to be established, some further gene 
expression studies and possibly some further trials would be worthwhile. In 
particular it would be useful to conduct further gene expression studies of the 
impact of myostatin antagonism on – MMPs, TIMPs, ActRIIB receptor expression, 
Smad-2/3 expression and activation, Smad-7 as a negative feedback inhibitor of 
myostatin and TGF-β, as well as hyaluronan and GAG levels in skin. A closer 
look at inflammatory processes and the factors involved thereof would provide 
further evidence of whether Mstn-ant4 can mimic the beneficial characteristics of 
foetal wound healing, given that foetal wounds heal with a lack of inflammation. 
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A skin wound healing trial could also be conducted with myostatin-null mice, 
which would provide a good model for the role of myostatin in skin healing. In fact 
there is anecdotal evidence that myostatin null mice heal with noticeably reduced 
scarring from incisional chest wounds resulting from heart surgery (McMahon and 
Matthews pers. com.). 
 
While the evidence presented here for a positive effect of a myostatin antagonist 
on burn wound healing in skin is credible, it does warrant further study. If 
anything, its role in wound healing, or at least skin hydration, could be a positive 
side effect for those being administered a myostatin antagonist for other medical 
conditions. 
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